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In this Special Issue we bring together papers demonstrating the need for both detailed genomic
and phenotypic studies to aid our scientific and clinical understanding of neurogenetic disorders.
Genomic techniques such as genome and exome sequencing are vital tools for diagnosing rare
neurogenetic disorders and identifying novel causal genes [1,2]. In this Special Issue, Gardner and
colleagues [3] utilise genomic techniques to identify a series of individuals with brain malformations
due to the recurrent TUBA1A p.Arg2His variant. This paper also describes the detailed phenotyping
required to aid in the interpretation of novel genomic variants. Variants in GBA1, the gene causing
Gaucher Disease (GD), are associated with an increased risk of Parkinson’s Disease (PD) [4,5].
Gatto and colleagues review this important area and describe how simple clinical observations
helped begin the identification of this important risk factor for PD [6]. Genomic techniques are crucial
for the diagnosis of neurogenetic disorders [7]. Garcia and Bustos [8] review the impact of such
techniques for both the diagnosis of neurogenetic diseases and increasing our scientific understanding
of these disorders. It is only through the co-development of both novel genomic and phenotypic
assessments that we will be able to fully understand the pathogenesis of neurogenetic disorders and
identify novel treatments.
Conflicts of Interest: The author declares no conflict of interest.
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Abstract: The TUBA1A gene encodes tubulin alpha-1A, a protein that is highly expressed in the
fetal brain. Alpha- and beta-tubulin subunits form dimers, which then co-assemble into microtubule
polymers: dynamic, scaffold-like structures that perform key functions during neurogenesis,
neuronal migration, and cortical organisation. Mutations in TUBA1A have been reported to cause
a range of brain malformations. We describe four unrelated patients with the same de novo
missense mutation in TUBA1A, c.5G>A, p.(Arg2His), as found by next generation sequencing.
Detailed comparison revealed similar brain phenotypes with mild variability. Shared features
included developmental delay, microcephaly, hypoplasia of the cerebellar vermis, dysplasia or
thinning of the corpus callosum, small pons, and dysmorphic basal ganglia. Two of the patients
had bilateral perisylvian polymicrogyria. We examined the effects of the p.(Arg2His) mutation
by computer-based protein structure modelling and heterologous expression in HEK-293 cells.
Brain Sci. 2018, 8, 145; doi:10.3390/brainsci8080145 www.mdpi.com/journal/brainsci3
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The results suggest the mutation subtly impairs microtubule function, potentially by affecting
inter-dimer interaction. Based on its sequence context, c.5G>A is likely to be a common recurrent
mutation. We propose that the subtle functional effects of p.(Arg2His) may allow for other factors
(such as genetic background or environmental conditions) to influence phenotypic outcome, thus
explaining the mild variability in clinical manifestations.
Keywords: TUBA1A; tubulin; p.(Arg2His), R2H; tubulinopathy; polymicrogyria; cerebellar hypoplasia
1. Introduction
TUBA1A is a highly-conserved gene with few changes among eukaryotes and few polymorphic
variants in human populations. TUBA1A encodes the tubulin alpha-1A chain, a protein that is
highly-expressed in the cerebral cortex, hippocampus, cerebellum, and brainstem of the developing
fetal brain, with a decrease in postnatal and adult stages [1,2]. Alpha- and beta-tubulin subunits
form dimers that coassemble into microtubules. Microtubules are dynamic polymers that perform
a range of mechanical tasks within the cell. As major components of the mitotic spindle, microtubules
control division of neuronal progenitors to produce neurons. In turn, they generate the push-and-pull
forces that are required for the migration of primitive neurons, from deep proliferative areas to the
cortical plate. Subsequently, bundles of stable and polarised microtubule polymers generate long
axons facilitating cortical organisation and synaptic connectivity.
TUBA1A was the first tubulin gene to be associated with human brain malformations [3].
Mutations in TUBA1A have been reported in patients with a range of brain malformations, including
lissencephaly, microlissencephaly, polymicrogyria, and simplified gyri [4–6]. They have also been
reported in patients with hydranencephaly-like dysplasias, cerebral palsy, and autistic spectrum
disorders [7–9]. TUBA1A mutations (as with other tubulinopathies) are often associated with
hypoplasia/agenesis of the corpus callosum, hypoplasia/dysplasia of the cerebellum, and dysmorphic
basal ganglia [5,6]. Common clinical features in TUBA1A patients include microcephaly, intellectual
disability, motor impairment, and epilepsy. Mutations in several other tubulin genes have been
reported in patients with brain malformations including TUBB2B [10], TUBB3 [11,12], TUBB [13],
TUBB2A [14], and TUBG1 [15]. However, TUBA1A mutations remain the most common cause
of tubulin-related brain malformations, with over 60 mutations being described to date [6].
Most disease-causing TUBA1A mutations are de novo, although familial recurrence due to parental
somatic mosaicism has been reported [4,16].
Pathogenic TUBA1A mutations have been found distributed throughout the gene. A handful
of recurrent TUBA1A mutations have been reported. These include the p.(Arg402His) mutation,
which has been reported in at least five patients and is associated with classic lissencephaly [3,17].
Similarly, the recurrent p.(Arg264Cys) mutation has been found in several patients and is typically
associated with central pachygyria [3,18,19]. Few genotype-phenotype correlations have been reported
for TUBA1A. However, the phenotypic effects of a specific recurrent mutation are generally consistent.
Alpha-tubulin must fold in a precise way and present specific shapes and charges on its surface to
interact with other proteins (e.g., beta-tubulin subunits, microtubule binding proteins) and to correctly
handle and hydrolyse guanosine-5′-triphosphate (GTP). Many TUBA1A mutations have been shown
to disrupt protein folding and/or heterodimer formation, resulting in either a reduced yield or reduced
stability [20].
During the clinical diagnostic work-up of two unrelated patients with developmental delay and
brain abnormalities, we identified the same mutation, c.5G>A, p.(Arg2His), in TUBA1A. To define the
clinical consequences of this mutation, we collected detailed phenotype information from both patients
and two additional patients that were previously reported in the literature [21–23]. We examined
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the functional impact of the mutation by in vitro microtubule studies and computer-based protein
structure modeling.
2. Materials and Methods
2.1. Patients
Patients 1 and 2 were diagnosed during routine clinical diagnostic work-ups. Patient 1 underwent
testing with a 12-gene polymicrogyria sequencing panel (targets enriched by Agilent SureSelect system,
followed by Illumina sequencing) in the United States. Patient 2 had testing with a 40 gene cortical
malformation gene panel (HaploPlex target enrichment system followed by Illumina sequencing) in the
United Kingdom. The mutations in Patients 1 and 2 were confirmed and shown to be de novo by Sanger
sequencing in the patient and both parents. Patient 3 underwent trio-based whole exome sequencing
(WES) as a part of their routine clinical diagnostic work-up in the United States [21,23]. The approach to
analysis and filtering of the WES data has previously been described [21]. No other candidate variants
were identified in the patient. Patient 4 underwent targeted sequencing of a panel of 423 genes that are
associated with corpus callosum anomalies in France [22]. The approach to analysis and filtering of this
panel has previously been described [24,25]. No other candidate variants were identified in the patient.
Consent was obtained from the parents of all the participants for publication. The genomic location of
the mutation is chr12:g.49580615C>T (GRCh37/hg19), rs587784491. Coding and protein positions of
TUBA1A mutations are based on GenBank accession codes NM_006009.3 (ENST00000301071.7) and
NP_006000.2, respectively.
2.2. Homology Modelling
Structural predictions of wild-type and mutant TUBA1A protein subunits were generated while
using a previously-described homology modeling pipeline [26]. This approach uses the solved
structure of a homologous template to predict the folding of a target sequence. The target sequence was
wild-type TUBA1A (NP_006000.2). The template used was the crystal structure of Tubulin alpha-1B
from Bos taurus (Protein Data Bank (PDB): 4I4T) [27], which shares 99% sequencing identity with human
TUBA1A. Microtubule architecture was based on a previously published template (PDB: 2XRP) [28].
Homology modelling was performed by MODELLER (version 9.17) [29]. Structural models were
viewed and analysed while using the UCSF Chimera software (version 1.12) [30,31].
2.3. Expression Construct Mutagenesis and Cell Culture
A C-terminally FLAG-tagged wild-type TUBA1A expression construct (pRK5-TUBA1A-C-FLAG)
was modified to generate TUBA1A-R2H by site-directed mutagenesis using the QuikChange
mutagenesis kit (Stratagene, La Jolla, CA, USA). HEK-293 cells were cultured in Dulbecco’s modified
Eagle’s media (ThermoFisher, Waltham, MA, USA, catalogue number 41966029), supplemented
with 10% fetal calf serum (ThermoFisher, 10500056) and 1% penicillin/streptomycin (ThermoFisher,
15070063), as previously described [14].
2.4. Immunocytochemistry
HEK-293 cells were cultured in Dulbecco’s modified Eagle’s media (ThermoFisher, 41966029).
supplemented with 10% fetal calf serum (ThermoFisher, 10500056) and 1% penicillin/streptomycin
(ThermoFisher, 15070063) and incubated at 37 ◦C 5% CO2. Cells were seeded onto poly-D-Lysine
(Sigma-Aldrich, St. Louis, MO, USA, P6407) pre-coated 13 mm glass coverslips. After 24 h,
the cells were transfected with either wild-type or mutant expression constructs using Lipofectamine
2000 (ThermoFisher, 11668030). Twenty-four hours post-transfection, the cells were fixed with methanol
at −20 ◦C for five minutes. Fixed cells were blocked with blocking buffer (phosphate-buffered saline
(PBS) with 2% Bovine Serum Albumin (BSA; Sigma-Aldrich, B4287) and 0.5% Triton (Sigma-Aldrich,
T8787)) for 30 min at room temperature (23 ◦C). Cells were immunostained with rabbit anti-FLAG
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(Sigma-Aldrich, F7425; 1:500) and mouse anti-alpha-tubulin (Sigma-Aldrich, T6199; 1:750) diluted
in PBS with 2% BSA and 0.1% Triton for one hour at room temperature. Primary antibodies were
aspirated, cells washed three times with PBS, and incubated with AlexaFluor568-conjugated goat
anti-rabbit (ThermoFisher, A11011) and AlexaFluor488-conjugated goat anti-mouse (ThermoFisher,
A11011) secondary antibodies for 30 minutes at room temperature, and protected from light from
this point onwards. Cells were rinsed with PBS, mounted onto glass slides with ProLong Gold
mounting medium (ThermoFisher, P10144) and stored at 4 ◦C until examined by confocal microscopy
(Zeiss Axioscope).
2.5. Predicting the Probability of TUBA1A Substitutions
The genomic DNA sequence of the TUBA1A gene (based on transcript ENST00000301071.7)
was obtained from the Ensembl Genome Browser [32]. A sliding window was implemented using
a Perl script. For each 7-nucleotide window the script recorded the position and base of the central
nucleotide. The heptanucleotide sequence was then looked up in the data from [33] (Supplementary
Table 7 from that paper). The substitution probabilities for changing the central nucleotide to each of
the three alternative bases were taken (averaging African, Asian, and European values). The cDNA and
protein consequences of each substitution were derived using Mutalyzer [34,35]. Predicted substitution
probabilities were obtained for all coding positions, introns (±20 base pairs flanking exons), and 5’ and
3’ untranslated regions (±20 base pairs).
3. Results
3.1. Clinical Features of Patients with the p.(Arg2His) Mutation
We identified two unrelated patients (Patients 1 and 2) with the same TUBA1A missense mutation,
c.5G>A, p.(Arg2His). A search of the literature found reports of two additional patients with the
p.(Arg2His) mutation (Patients 3 and 4) [21–23]. Only brief descriptions of the two published subjects
were previously available. We obtained detailed clinical information from the four individuals (Table 1,
detailed case reports are provided in the Supplementary Material). All four mutations were de novo.
Consistent features in the living patients were developmental delay and microcephaly. MRI brain
images from Patients 1–3 were available for review (Figure 1). The images demonstrated the hypoplasia
and dysplasia of the cerebellar vermis (3/3), hypoplasia or dysgenesis of the corpus callosum (3/3),
and dysmorphic basal ganglia (3/3). Patient 1 had bilateral perisylvian polymicrogyria. The pons of
all three patients was small, particularly affecting the belly of the pons.
Patient 4 was a fetus terminated at 36 weeks gestation. Post-mortem examination of Patient
4 found a small brain (weight on 5th centile) with shortening of the corpus callosum and cerebellar
hypoplasia (Figure 2A,B). Neuropathology examination found bilateral perisylvian polymicrogyria
(Figure 2C–E). At the supratentorial level, callosal fibers and corticospinal tracts (CST) were hypoplastic.
The brainstem was shortened and dysmorphic, displaying a Z-shaped kink. At the level of the cerebral
peduncles, the CST were present but reduced in size. The pons was reduced in size in its basilar part.
In the pons the CST were present at the junction with the peduncles but showed a chaotic pattern in
between the pontine nuclei. The transverse pontine fibers were also reduced, and associated with
cerebellar heterotopias and hypoplastic deep nuclei. At the level of the medulla, the pyramids were
present but hypoplastic. The inferior olivary nuclei were also reduced in size. Neuronal heterotopia of
the olivary nuclei was noted. At the cervical spinal cord level, crossing CST were absent. Cerebellar
foliation was normal, but lamination was impaired with rare and misaligned Purkinje cells.
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Table 1. Clinical features of patients with the recurrent p.(Arg2His) TUBA1A mutation.
Patient 1 2 3 4 (fetus)
Sex Male Male Male Male
OFC at Birth 30 cm (−3.6 SD) 34 cm (−0.9 SD) 33 cm (−1.7 SD) n/a
Age at last review 4 years 32 months 37 months TOP at 36 weeks gestation
Last OFC 45 cm (−4.9 SD) 43 cm (−5.9 SD) 45 cm (−4.6 SD) n/a
Developmental delay Moderate Severe Moderate n/a






White matter Reduced Reduced Reduced n/k
Corpus callosum Partial agenesis Thin Thin Short, no rostrum
















Key: n/a/k = not applicable/known; OFC = occipital frontal circumference; PMG = polymicrogyria; SD = standard
deviations; TOP = termination of pregnancy.
 
Figure 1. Magnetic resonance images from patients with the recurrent p.(Arg2His) TUBA1A mutation.
T2-weighted axial and T1-weighted midline sagittal brain images for Patient 1 at age three years (A–C),
Patient 2 at age six months (D–F), and Patient 3 at age 19 months (G–I). The images demonstrate
hypoplasia and dysplasia of the cerebellar vermis (yellow arrows), thinning or partial agenesis of the
corpus callosum (red arrows), globular basal ganglia with incomplete formation of the anterior limb
internal capsule (white arrows), and bilateral perisylvian polymicrogyria (blue arrows). The pons is
similar in size to the midbrain which suggests the pons is relatively small (C,F,I).
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Figure 2. Neuropathology from Patient 4. (A) The medial aspect of right cerebral hemisphere showing
a thin corpus callosom with absent rostrum. (B) Midline sagittal section of brain stem and cerebellum
showing mild hypoplasia of the cerebellar vermis. (C) Coronal section of the cerebral hemispheres.
The corpus callosum is thinned and there is thickening of the cortex around the sylvian fissures.
(D) Stained section of the right cerebral hemisphere revealing abnormal folding of the cortical ribbon
around the sylvian fissure. (E) A magnified view of (D) demonstrating polymicrogyria around the
sylvian fissure.
3.2. Modelling the Structural Effects of p.Arg2His
The Arg2 residue of TUBA1A is highly conserved across species and tubulin isoforms (Figure S1).
The p.(Arg2His) variant is not present in gnomAD and multiple in silico prediction tools suggest it
is deleterious (Table S1). However, the physicochemical difference between arginine and histidine
is relatively small (Grantham difference 29) with both of the residues having positively-charged
side chains. The c.5G>A change is predicted to have minimal effects on the splicing at the adjacent
splice acceptor site (Figure S2). When incorporated into polymerised microtubule, the N-terminus
of alpha-tubulin is positioned near the inter-dimer interface, between the alpha-tubulin subunit of
one heterodimer and the beta subunit of the next heterodimer. To study the effects of p.Arg2His
on the three-dimensional structure of the protein, we compared wild-type and mutant TUBA1A by
modelling the alpha/beta-tubulin heterodimer (Figure 3A,B) (the protein variant is given here without
brackets as we know the amino acid sequence in a simulation). The effects of the mutation were mild.
No predicted hydrogen bonding was lost or gained between the alpha- and beta-tubulin subunits as
a result of p.Arg2His. A hydrogen bond between Arg2 and the highly-conserved Cys4 residue within
TUBA1A was lost. In addition, new bonds between Glu3, and both Asn50 and Thr130 were predicted
to form as a result of the substitution. Additional conformational changes were predicted to occur in
a loop region (Asp38 to Asn51, Figure 3B), which may affect interactions between heterodimers.
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Figure 3. In silico modelling and in vitro functional analysis of the p.(Arg2His) mutation. (A) Ribbon
models of alpha-tubulin (green) and beta-tubulin (blue) subunits aligned in a microtubule polymer.
The position of Arg2 is shown (arrow) close to the inter-dimer interface (between alpha-tubulin and
the beta-tubulin of an adjacent heterodimer). The mutation is on the opposite side of TUBA1A from
the binding site of guanosine-5′-triphosphate (GTP, orange). (B) A close-up view of the Arg2 residue
(arrow) with the mutant (purple ribbon, red side chain) and wild type (green ribbon and side chain)
proteins superimposed. Only mild confirmation changes are predicted around the Arg2 residue.
However, additional conformational changes are predicted between residues 38 and 51 (bracket).
These may affect the interaction between heterodimers. (C) HEK-293 cells expressing FLAG-tagged
TUBA1A-R2H. The cells are stained with DAPI (4′,6-diamidino-2-phenylindole, blue), anti-FLAG- (red),
and anti-alpha-tubulin (green) antibodies. The microtubules appear yellow due to the colocalisation of
endogenous (green) and FLAG-tagged transgenic (red) tubulin. The arrows indicate diffuse patches
of transgenic mutant tubulin (red) in the cytoplasm between the microtubules. (D) Control cells
expressing FLAG-tagged wild-type TUBA1A have less staining for the transgenic tubulin in the
cytoplasm between the microtubules.
3.3. Heterologous Expression of TUBA1A-R2H in HEK-293 cells
TUBA1A containing the p.(Arg2His) mutation (TUBA1A-R2H) was expressed in cultured HEK-293
cells. TUBA1A-R2H incorporated into the microtubule polymer network (Figure 3C), suggesting that it
successfully folds and dimerises with endogenous beta-tubulin. However, in comparison to wild-type
TUBA1A (Figure 3D), there was a slight increase in the proportion of the mutant FLAG-tagged
protein seen unpolymerised within the cytosol. This suggests the mutation subtly alters the function
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(folding, dimerisation, or coassembly) of the subunit, but that once incorporated the dynamics of the
mutant subunit are similar to wild type.
3.4. Substitution Probability of Recurrent TUBA1A Mutations
The observation of p.(Arg2His) on four separate occasions suggested that it was a common
recurrent TUBA1A mutation. However, we noted that p.(Arg2His) had not been reported in
previous large tubulinopathy cohorts [6]. In contrast, several TUBA1A mutations have been found
recurrently in tubulinopathy patients. Examples include p.(Arg214His) [6,36], p.(Arg264Cys) [3,18,19],
p.(Arg390Cys) [17,37], p.(Arg402His) [3,17,38,39], p.(Arg402Cys) [17,19], and p.(Arg422His) [17,18,40].
This made us wonder whether p.(Arg2His) had a lower mutation rate than the other recurrent TUBA1A
mutations or whether it was just ascertained less frequently. We observed that the recurrent mutations
all occurred at CpG sites, which are prone to spontaneous deamination (CGx is the codon for arginine).
This highlighted that sequence context was likely to be an important factor. To predict the substitution
rates at these sites and to compare them with the rest of TUBA1A, we estimated the probability of
all possible single-base substitutions in TUBA1A based on heptanucleotide context (target position
and three flanking nucleotides either side). Heptanucleotide context has been shown to explain >81%
of variability in substitution probabilities [33]. We found the seven recurrent TUBA1A mutations all
ranked in the top 1% for substitution probability. The p.(Arg2His) mutation was the second highest in
the group (ranking 7th out of 4548 possible substitutions) (Table S2). These results suggest p.(Arg2His)
has a mutation rate that is similar to other recurrent TUBA1A mutations. The lack of observations in
previous tubulinopathy cohorts may therefore reflect differences in ascertainment.
4. Discussion
In this report, we describe four patients with the TUBA1A p.(Arg2His) mutation. The patients had
similar phenotypes with mild variability. Shared features included developmental delay, microcephaly,
hypoplasia, and dysplasia of the cerebellar vermis, dysplasia or thinning of the corpus callosum, and
dysmorphic basal ganglia. The pons tended to be small, disproportionally affecting the belly of the
pons. We suspect the pons is dyspastic (i.e., abnormally developed) as well as small. Histopathological
abnormalities of the pons were noted in patient 4. Two of the patients had bilateral perisylvian
polymicrogyria. These features are typical of a tubulinopathy spectrum disorder [6]. Our findings
suggest that p.(Arg2His) is a common recurrent TUBA1A mutation. Tubulinopathy patients are often
ascertained due to cortical malformations (e.g., the classical lissencephaly associated with the recurrent
p.(Arg402His) mutation)). In contrast, p.(Arg2His) does not cause an extensive cortical malformation.
This may explain why p.(Arg2His) has not been observed in previous tubulinopathy cohorts [6].
Phenotypic variability that is associated with recurrent TUBA1A mutations has previously
been noted. For example, the p.(Arg390Cys) mutation was first reported in a patient with mild
gyral simplification, complete agenesis of the corpus callosum, and cerebellar hypoplasia [17].
It was subsequently reported in a patient with asymmetrical perisylvian polymicrogyria, hypoplasia
of the corpus callosum, dysplastic cerebellar vermis, dysmorphic basal ganglia, and severe
hypoplasia of brainstem [37]. Similarly, p.(Arg214His) was initially reported in a fetus with central
polymicrogyria-like cortical dysplasia, complete agenesis of the corpus callosum, and normal
cerebellum [6]. It was then reported in a patient with diffuse irregular gyration and sulcation of
the cortex, partial agenesis of the corpus callosum, hypoplasia of the cerebellar vermis, and globular
thalami [36]. As with p.(Arg2His), these descriptions suggest variability, but with overlap in key
elements of the phenotype (abnormalities of the cortex, corpus callosum, cerebellum, and basal ganglia).
Some of the variability may be due to differences in the interpretation of the brain imaging. However,
differences in genetic background, environmental factors, or random chance may also contribute.
Oegema et al. [36] found that p.(Arg214His) caused only a mild functional deficit (incorporating
into microtubule polymers at comparable levels to wild type but at a reduced rate) and subtle
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predicted structural effects. Mutations with relatively mild functional effects (such as p.(Arg214His) or
p.(Arg2His)) may allow for other factors to influence phenotype outcome.
Mutations of the homologous Arg2 residue in other tubulin isoforms have been linked to human
disease phenotypes. TUBB8 is the main beta-tubulin of oocytes. The p.(Arg2Lys) mutation in TUBB8
has been found to cause arrest of oocyte meosis [41]. The mutation is thought to affect folding of the
protein as well as the assembly and stability of heterodimers. The p.(Arg2Met) mutation in TUBB8
has also been shown to cause arrest of oocyte maturation [42,43]. TUBB4A is a brain-expressed
beta-tubulin isoform. A p.(Arg2Gly) mutation in TUBB4A has been identified in a family with dystonia
type 4 (‘Whispering dysphonia’) [44,45]. TUBB4A p.(Arg2Trp) and p.(Arg2Gln) have been reported to
cause hypomyelination with atrophy of the basal ganglia and cerebellum [46,47]. The Arg2 of TUBB4A
is part of the MREI (Met-Arg-Glu-Ile) ‘auto-regulatory’ domain, which is involved in controlling the
amount of the beta-tubulin produced by the cell. In addition, these mutations disrupt a salt bridge
Arg2 forms with Asp249 in TUBB4A [48]. This salt bridge is not predicted to occur in TUBA1A as the
homologous residues are further apart.
5. Conclusions
We have shown that the TUBA1A c.5G>A, p.(Arg2His) mutation causes cortical, callosal,
and cerebellar abnormalities that are typical of tubulinopathy-associated brain malformations.
Based on its sequence context (and observation in four unrelated patients), c.5G>A is likely to
be a common recurrent mutation in TUBA1A. Our functional and computer modelling results
suggest that p.(Arg2His) has subtle effects on microtubule function, possibly acting at the inter-dimer
interface. We propose that the subtle functional effects of the mutation may allow for other factors
(e.g., genetic background, environmental conditions, or random chance) to modulate outcome,
explaining the mild phenotypic variability observed.
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Abstract: Quantifying gait and postural control adds valuable information that aids in understanding
neurological conditions where motor symptoms predominate and cause considerable functional
impairment. Disease-specific clinical scales exist; however, they are often susceptible to subjectivity,
and can lack sensitivity when identifying subtle gait and postural impairments in prodromal cohorts
and longitudinally to document disease progression. Numerous devices are available to objectively
quantify a range of measurement outcomes pertaining to gait and postural control; however, efforts
are required to standardise and harmonise approaches that are specific to the neurological condition
and clinical assessment. Tools are urgently needed that address a number of unmet needs in
neurological practice. Namely, these include timely and accurate diagnosis; disease stratification;
risk prediction; tracking disease progression; and decision making for intervention optimisation and
maximising therapeutic response (such as medication selection, disease staging, and targeted support).
Using some recent examples of research across a range of relevant neurological conditions—including
Parkinson’s disease, ataxia, and dementia—we will illustrate evidence that supports progress against
these unmet clinical needs. We summarise the novel ‘big data’ approaches that utilise data mining
and machine learning techniques to improve disease classification and risk prediction, and conclude
with recommendations for future direction.
Keywords: movement science; Parkinson’s disease; ataxia; dementia; machine learning; deep
learning; risk prediction; disease phenotyping
1. Introduction
Quantifying movement through clinical observation is central to enhancing our understanding of
neurological disorders. It informs diagnosis, disease severity, progression, and therapeutic response.
Mobility deficits (particularly gait and postural control, which form the focus of this review) provide
critical information relevant to the diagnostic process. The clinical assessment of gait and posture
within an outpatient, inpatient, or rehabilitation setting typically takes the form of self-report, subjective
scales, and observation. Validated gait and postural control rating scales and assessments are also
commonly applied (e.g., the Tinetti Performance-Oriented Mobility Assessment [1], the Dynamic
Gait Index [2], and the Berg Balance Scale [3,4]). Although helpful in terms of change over time
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and considered the gold standard in clinical settings, significant limitations exist, due to variation,
subjectivity, inconsistency, and poor granularity. Moreover, as we move to an era where the focus
is on earlier detection, different tools are needed with greater sensitivity to detect change than is
currently offered.
Traditional approaches to quantify gait and postural control have relied upon complex and
expensive laboratory equipment and specialist expertise, which lack translation to the clinic.
Developments in movement analysis devices such as reduced prices and improved automated software
are now facilitating their applicability not only to clinics but also for continuous monitoring on a large
scale within real-world settings. The opportunity for better protocol standardisation, the harmonisation
of outcome measures, and assessments of large cohorts through multi-centre studies in this evolving
field are a welcome consequence. Equally welcome is the opportunity for improved stratification for
clinical trials of novel neuroprotective therapies and disease progression. In an era of personalised
medicine and early detection of risk, subtle changes in movement consequent to neurodegenerative
disease would also improve clinical management through timely and accurate diagnosis and tracking,
disease stratification, risk prediction, and enhanced decision making for intervention optimisation
and maximising therapeutic response (such as medication selection, disease staging, and targeted
support). In turn, the improved information provided with the correct interpretation may improve
independence, quality of life, and a reduction of fall risk for patients.
Throughout this review of the scientific literature, we will focus on the role of quantitative
movement analysis in neurodegenerative disorders and restrict our discussion to the measurement of
gait and postural control measured during standing in key conditions. The review has four sections,
each of which addresses a key aim. Section I aims to provide an overview of the strengths and
limitations of current measurement techniques/devices, outcomes, and protocols relevant to key
measurement needs. Section II aims to provide evidence to support the use of gait and postural control
as clinical biomarkers as defined above, drawing from studies in Parkinson’s disease (PD), ataxia, and
dementia. Section III aims to highlight new and emerging areas relating to bioinformatics (data mining
and machine learning) and what we can learn in the context of disease classification, phenotyping, and
risk prediction. Finally, Section IV offers recommendations for future work in this field.
2. Section I: Quantitative Movement Analysis: From Measurement Tools to Outcome Measures
Below, we provide a brief overview of the measurement tools, protocols, and quantitative outcome
measures that are currently utilised, highlighting the most relevant (Figure 1 and Table 1).
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Figure 1. Summary of outcome measures that may be obtained from a quantitative assessment of gait
and postural control.
Table 1. A summary of the advantages and disadvantages of measurement devices used to quantify
gait and postural control. COP: center of pressure.
Device Advantages Disadvantages
3D motion capture
- Considered the gold standard
- Highly precise and accurate





- Requires experienced technical expertise
- Requires a large purpose-built dedicated space
usually limited to laboratory/research
environments
- Participant preparation can be time-consuming
Force plates
- Considered gold standard for measuring
ground reaction forces and COP
- Non-invasive
- Minimal space required
- Minimal participant preparation time
- High-resolution data
- High cost
- Requires experienced technical expertise
- Requires a purpose-built dedicated space
Instrumented mats
- Minimal processing time
- Non-invasive
- Minimal participant preparation time
- Portable
- Extractable features are limited by mat
dimensions
- Requires a large space to accommodate the mat
dimensions
- Limited to temporal spatial and foot pressure
gait outcomes of the lower extremities
Inertial measurement units
- Capable of capturing continuous movements
in laboratory and community environments
- Non-invasive with minimal participant
preparation time
- Certain systems provide automated reports
- Cheaper than the gold standard
- Portable
- Often requires complex algorithms and special
expertise to extract key features
- Features are often indirect measures requiring
additional participant measurements
- Free-living measurements may be limited by
recording time (if battery powered) or data
storage (if data is stored internally on the device)
Accelerometer
- Low cost
- Wearable, wireless technology capable of
capturing continuous movements in lab and
community environments for prolonged
periods (>one week)
- Non-invasive
- Minimal participant preparation time
- Portable
- Often requires complex algorithms and special
expertise to extract key features post-data
collection
- Features are often indirect measures requiring
additional participant measurements
- Data collected in community living
environments lack context
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2.1. Quantifying Gait and Postural Control—Which Tools?
For an objective, quantitative analysis of gait and postural control, three-dimensional motion
analysis, footswitches, instrumented walkways, body-worn sensors, pressure mats, force platforms,
posturography, and electromyography are the most common tools, each with their own strengths and
limitations. Quantitative tools can be as simple as a stopwatch, which with a known distance, can
be used to gain clinically relevant measures such as gait speed [5]. The main consideration when
deciding the best approach is the need to balance the requirement for better granularity, sensitivity,
specificity, measurement accuracy, and minimal rater bias, with the complexity and feasibility of using
such methods in clinics, communities, and clinical trials (Table 1).
Three-dimensional motion analysis systems are capable of measuring movements of the whole
body; they can measure both gait and postural control, are highly accurate and precise, and are relied
upon as the gold standard to compare new tools as well as to evaluate the benefit of therapeutic
interventions (e.g., surgical procedures, pharmacological therapies, assistive devices, and exercise
training programs) [6]. However, the high cost, long preparation time, and need for specialist staff
to operate these systems are barriers to their wholesale adoption within routine clinical care [7].
Furthermore, even when clinically implemented, the choices regarding protocols such as different
marker sets and biomechanical models, which are needed to quantify kinetics and kinematics,
combined with the complexity of the outputs, can greatly influence the outcome and decisions based
on the data collected [8]. This means that these systems are largely limited to research settings.
Instrumented mats provide reliable quantitative spatiotemporal gait characteristics of the feet at a
lower cost relative to three-dimensional motion analysis, while also providing pressure information [9–11].
They can provide a number of gait outcomes ranging from information on pace to dynamic postural
control [12]. If located in a dedicated space, the preparation time for the device and the participant is
minimal. Additionally, most systems come packaged with accompanying software that is capable of
generating automated reports, meaning that specialist support may not always be required. Limitations
include: the devices are not easily portable and require large indoor spaces, are not capable of
measuring standing balance, and that due to the finite size of the mat, multiple trials are required to
generate reliable gait measures [13].
More recently, technological advances in wearable devices allow an alternative to traditional
laboratory-based and clinical assessments of gait and postural control. Wearable sensors are mobile
devices that are designed to be worn on the body, or embedded into watches, bracelets, and
clothing [14]. They may be used in the clinic, but also in free living. This opens a whole new
perspective in terms of assessing mobility over extended periods of time [15–18] while concurrently
evaluating traditional and novel measures of gait [19,20], quantitative measures of physical activity [21],
and postural outcomes such as transitions and turns [22,23]. The inclusion of free-living data
alone or in addition to clinical assessment provides vital information that may help inform the
diagnosis and monitoring of neurological disease. However, whilst these new avenues and variables
appear promising, the best combination of methods and metrics are still to be determined [15,24].
However, limitations with wearable devices should be considered. Although a single accelerometer is
inexpensive relative to the other more traditional devices highlighted above, multiple sensor systems
with accompanying software that is capable of calculating outcome measures into reports dramatically
increase the price. Also, with such systems, clinicians require methodological training, which is critical
for avoiding blind interpretations of erroneous reports. Lastly, although many proxy measures of
gait have been validated [25,26], many algorithms for their estimate and novel measures have not,
meaning that further effort is needed in order to create robust, validated, and population-specific
normative values.
2.2. Outcome Measures and Data Collection Protocols
Below, we provide a brief summary of some of the most common outcomes from quantitative
analysis that are used to describe gait and postural control (Figure 1). Gait and postural control are
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intimately related. Gait models include measures that reflect aspects of gait-related postural control,
and can be interpreted as such. However, for the purposes of this review and to reflect how assessment
is commonly conducted, we address each independently.
For gait, the most common outcome is gait speed because of its robust clinimetric properties [5,12].
Often regarded as a global measure of overall function, gait speed is informative; however, it does
not reveal the specific gait deficit (i.e., temporal or spatial control of gait), and as such is limited [12].
Moreover, in laboratory and clinical settings, gait speed may also be susceptible to the ‘Hawthorne
effect’, whereby participants perform particularly well in controlled environments whilst being
observed [27]. Many other outcomes can be used to describe gait, and may add greater specificity
regarding differentiating between neurological conditions and increased sensitivity when evaluating
subtle within-person changes [12,28]. To aid interpretation, normative values have been published
and serve as reference data [29,30], and conceptual models of gait have been developed to provide a
more structured approach [12,31,32].
The measurement of gait can be broadly grouped within a structure that captures: (1)
spatiotemporal features that reflect a typical gait cycle, which is expressed as the average of multiple
steps over a specified distance; and (2) dynamic features of gait, which represent the step-by-step
inconsistency of spatiotemporal measures across these steps [12]. These dynamic features are typically
represented by the within-person standard deviation (SD) or the coefficient of variation [33]. Hausdorff
(2009) [34] also introduced a broader definition of the dynamic features of gait that incorporated
the underlying structure and pattern of movements in gait derived from data collected over longer
periods. These long-term, fractal-like correlations break down with age and disease, and as such,
different measures reflecting the variability of movement may provide additional sensitive markers of
early/prodromal disease [34].
Standardised protocols for the assessment of gait (for a recent review, see [35]) typically measure
gait at a preferred walking speed over four metres, and are clinically applicable [36]. Departure from this
protocol is acceptable for some gait characteristics, but not for others. Gait speed is reliable over 10 m
or six minutes, for both preferred and fast walking, and in clinic and home environments [26,37–40].
This is not the case for gait variability, where clinimetrics improve with a greater number of steps,
and a minimum of 30 steps is advocated [13,41,42]. Walking over longer durations (e.g., two and
six-minute walking tests) are also commonly used to infer endurance [43]. Protocols are also modified
to provide additional challenge; these are so-called “stress tests”. They include dual-task paradigms,
turning, backward walking, and walking at a fast pace [44]. Dual-task testing paradigms (i.e., asking
someone to recall a sequence of numbers while walking) are employed to reduce the compensatory
cognitive control of gait, revealing latent motor deficits; as a consequence, they also expose the level of
compensatory cognitive control that is required to maintain gait performance.
A range of outcomes exist for measuring postural control during standing. Typically, they are
derived from either movements of the center of mass (COM) or the center of pressure (COP), and
can be summarised as linear and non-linear outcomes (see Figure 1). Linear parameters and derived
indexes provide information about the direction (e.g., anterior–posterior or mediolateral directions)
and global ‘magnitude’ of postural sway (e.g., root mean square (RMS), limits of stability, jerk, ellipsis),
and the fluctuation of COM or COP displacement (frequency domain metrics) [45–52]. Non-linear
outcomes describe the regularity or predictability of balance control [53].
The protocols that are used to assess postural control vary greatly from quiet standing to standing
barefoot or with shoes on, on a foam support or firm surface, with eyes open or closed (Romberg
test), with either standardised or unrestricted foot placement, with arms across the chest or by their
sides, and over different trial durations ranging from 30 to 120 seconds [48,51,53–56]. To date, postural
control outcomes are typically summarised over the test duration, which may limit comparability
across protocols of varied duration, as most linear metrics are time-dependent and thus influenced by
test duration. For example, a person’s total COM excursion will increase relative to time, highlighting
the need for normalisation and standardised protocols for between-investigation comparisons (for a
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detailed description of how method can impact postural control measures, please see [57]). Alterations
in postural control over discrete windows of time may provide a more subtle reflection of postural
adaptations in addition to outcomes averaged across the test duration [56].
In summary, the breadth of tools that are used to measure gait and postural control are vast, as
are the range of protocols for data collection and the outcome measures that are extracted. Therefore,
there is a need to standardise and harmonise approaches. Currently, the optimal testing battery for
gait and postural control applied either independently or in combination is unknown, and further
work is needed to define this on a disease-by-disease basis, and also with respect to the purpose
(e.g., diagnosis, progression, risk prediction), as one size will not fit all. The opportunity for the
uncontrolled continuous monitoring of gait and postural control during free-living activities is an
area of considerable interest, and its additional measurement holds promise for the future. A growing
number of outcomes may be obtained ranging from the micro (i.e., step length and time) to the
macro (i.e., total time walking per day) features of gait. However, the optimal approach to integrate
free-living movements into clinical decision making is yet to be defined, and this continues to be an area
of emerging interest. Despite this, the promise of movement analysis for diagnosing and monitoring
neurological conditions is becoming increasingly evident, and examples from recent literature are
highlighted in Section II across a range of different disease groups.
3. Section II: Distinguishing Features of Gait and Postural Control across
Neurodegenerative Conditions
In this section, we highlight examples from the recent literature to illustrate the value of
instrumented assessment of gait and postural control across a range of different disease groups.
3.1. Parkinson’s Disease
Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s
disease (AD), affecting one in every 500 adults in the United Kingdom (UK) and up to 10 million
worldwide [58–60]. PD was previously described as a degeneration of dopaminergic cells in the
substantia nigra; however, a more contemporary understanding of PD highlights that it is a complex
multi-system disorder that is represented clinically by a syndrome with multiple neurotransmitter
deficits (for a recent review, see [61]). A variety of clinical assessment scales have been designed
to evaluate the motor symptoms of PD (including gait and postural control) such as the Unified
Parkinson’s disease rating scale Part 3 (UPDRSIII [62]) and the Hoehn and Yahr scale [63]. They
are embedded within routine clinical evaluation and categorically grade disease severity and motor
symptoms from normal to severe. As such, they often do not capture detailed information regarding
motor deficits, may miss subtle within-person changes, and can be susceptible to variation when
administered by different assessors.
The quantification of gait characteristics in PD can inform risk [64], progression (including
response to treatment) [65], and diagnosis [66]. Notably, discrete gait changes predict both future
falls [67,68] and cognitive decline in incident PD [69], raising the possibility of a target for a preventative
approach in early disease. Subtle and discrete differences have been identified in early PD compared to
age-matched controls, with reduced step length, increased asymmetry, and step-to-step variability [65].
Gait impairments evolve over time from a subtle, discrete picture to a more global presentation of
deficit in all its characteristics [65,70,71]. Subtle gait impairments are also present in individuals with
Parkinson’s ‘at risk’ syndromes such as rapid eye movement (REM) and sleep behavior disorder (RBD)
prior to the development of Parkinsonian features (so-called ‘prodromal’ disease) when compared to
healthy controls without risk factors [72].
Monitoring upper-body movements (such as the magnitude of arm swing or movement of the
trunk) during walking is emerging as a powerful measure complementary to traditional gait analysis
(measuring stepping characteristics), and has been shown to be capable of discriminating PD from
controls [24,73], and PD fallers from non-fallers [74–76]. Arm swing variability during gait has also
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been identified as a distinguishing feature in carriers of the G2019S mutation, which was significantly
different to both non-carriers and people with PD [77]. This has raised the possibility of upper body
movements during gait as a clinical biomarker for PD to enhance diagnostic accuracy, which in early
disease may only be between 70–80% [78], and supports the use of quantitative, objective assessments
to measure changes that may not be detected during routine clinical observation.
Gait continues to deteriorate even in the early stages of the disease despite optimal medication
with evidence to suggest that some discrete characteristics of gait are dopa-resistant (i.e., step length,
step width, and swing time) [65,71]. Other gait characteristics appear to be responsive to intervention,
with a recent review of pharmacological therapies highlighting the role of cholinesterase inhibitors
to improve gait variability [79]. Therefore, quantitative movement analysis may be useful when
understanding the effectiveness of levodopa, and potentially highlight when alternative treatment
options may be required. Deficits in gait have been linked to primary pathophysiology, as visualised
with functional and structural neuroimaging, cerebral spinal fluid, and blood-based biomarkers,
supporting the use of discrete gait characteristics as potential clinical biomarkers to track pathology.
Gait impairments such as gait speed may be attributed to underlying cholinergic dysfunction [80,81],
with evidence to suggest that amyloid proteinopathies may also contribute to the progression of
dopa-resistant gait characteristics (step time and length variability) [71]. Freezing of gait (FOG)
is a debilitating symptom that often affects patients with advanced PD, and has shown a positive
response to levodopa [67]. FOG is recognised as an episodic absence or marked reduction of forward
progression of the feet, despite the intention to walk [82], and is associated with an impaired regulation
of stride variability [83–86]. A recent report explored the potential use of smartphones to assess digital
biomarkers of PD, including gait and postural control, and to identify exploratory outcome measures
for Phase I clinical trials [87]. The results revealed acceptable adherence and moderate to strong retest
reliability (Intraclass Correlation Coefficient = 0.84), highlighting the potential of using smartphones
to collect gait and postural control data. Not only were people with PD distinguished successfully
from controls, the analysis of turning (possible with accelerometer and gyroscope-derived measures)
offered increased sensitivity compared to traditional clinical scales [87].
Previous research quantifying the linear parameters of postural control has suggested that:
(i) abnormalities in postural control during quiet standing exist even in early PD [45,46,56]; (ii) linear
parameters can differentiate between PD motor subtypes [88]; and (iii) as disease symptoms progress,
sway parameters deteriorate, especially in the mediolateral direction [45]. The positive effect of
dopaminergic replacement therapy that has been observed for gait may not be paralleled for postural
control, where levodopa has been shown to worsen some outcomes [50]. Non-linear measures of
postural control have shown that people with PD display lower predictability/regularity of the COM
along all sway directions; this may be explained by the loss of constant fine adjustments of posture
due to impaired sensorimotor integration and the disturbance of habitual motor control pathways [53].
However, it is still unclear whether regularity metrics are sensitive to disease progression [53,89].
However, practically, monitoring the positive and negative influence of therapies may be useful in
clinical management and falls risk.
3.2. Ataxia
The prevalence of hereditary cerebellar ataxias is estimated at 2.7/100,000 (average derived from
meta-analyses [90]). Ataxia describes a collection of neurological disorders affecting the cerebellum
that impair the control and coordination of whole body movements, eye movements (nystagmus),
and speech (dysarthria) [44,91,92]. Consequently, the integration of sensory information to coordinate
voluntary movements is challenged, and impairs gait and postural control. Poor gait control is often the
initial symptom in ataxia groups [93], reportedly occurring in around 60% of ataxia patients [94], and in
some cases emerging prior to the onset of neurological symptoms [95]. Quantitative movement analysis
has shown that ataxic gait is associated with slower walking speeds and a reduced cadence, a shorter
step and swing phase duration, a longer double limb support phase, wider steps, and increased
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gait variability (particularly step length and width) [96–104]. Impaired gait and postural control are
associated with an increased falls risk [99,105,106], and serve as attractive targets for intervention (refer
to [107,108] for comprehensive reviews of gait and balance, respectively). Falls are common in people
with ataxia, occurring in up to 74%, and prevalence is proportionate to other neurological conditions
such as PD [109]. We draw upon examples of inherited and secondary ataxias [110,111] to highlight
the importance of quantitative analysis of gait and postural control in this patient group. While broad
clinical scales such as the Scale for the Assessment and Rating of Ataxia (SARA) [112] provide an
indication of overall function, they are unable to reveal the nature of subtle movement impairments in
this patient group. Quantifiable, objective measures that may be used as markers to document gait
and postural impairment are lacking when relying on these clinical scales alone. Gait variability, in
particular variability in the timing of movement, is specific to cerebellar dysfunction [113], and cannot
be assessed using clinical scales.
Patients with ataxic symptoms, including individuals with multiple sclerosis, display deficits
in postural control including a greater magnitude and speed of postural sway [97,114], which is
attributed to a reduced range of motion at the knee (‘locked knees’) and a delayed response in muscle
activity [115]. To compensate for this poor postural control, people with ataxia often widen their stance
(base of support) to stabilise the head and trunk [116]. Anterior–posterior falls are more common than
falls in the mediolateral direction [117]. Accordingly, assessment protocols that assess balance in the
anterior–posterior direction pose a heightened challenge for people with ataxia [118,119].
Quantifiable measurement outcomes obtained during gait are useful for distinguishing ataxia
and mitochondrial disease from controls and other neurological conditions such as PD and hereditary
spastic paraplegia (HSP) [100,120,121]. For example, patients with mitochondrial disease walk slower,
with a shorter step and increased step width variability during normal and dual task walking compared
to controls [120]. In contrast, patients with ataxia walk with an increased step width and larger ankle
range of motion compared to controls, PD, and HSP [100]. Quantifying gait using wearable sensors
is a valid measure for use with mild to moderate ataxia [26], with the mediolateral acceleration of
the upper body during gait in particular being specific to disease and sensitive to symptom severity.
Therefore, this may serve as a clinical biomarker for ataxia [122]. Gait outcomes extracted using more
complex non-linear and data-driven approaches also offer potential, and are able to differentiate
ataxias from other neurological patient groups [99,100,103]. Complex walking tasks such as incline
walking [123], obstacle avoidance [124,125], and turning [102,122,126] may serve as ‘stress tests’ to
exacerbate underlying gait impairments in ataxia and identify preclinical changes in this patient
group [127].
3.3. Dementia
Dementia is a neurodegenerative syndrome that is characterised by multiple cognitive
impairments affecting social and/or occupational functioning [128,129]. Globally, almost 50 million
people are affected, the majority of whom are aged over 65. Risk increases exponentially with age,
leading to high socioeconomic costs [130,131]. Dementia has many subtypes driven by different
pathologies, the most common incorporating: Alzheimer’s disease (AD); Lewy body dementias (LBD),
which is comprised of dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD); and
vascular dementia (VaD). Mild cognitive impairment (MCI) may also be a risk factor for dementia, and
can also be classified into subtypes [129,132]. The early and accurate identification of dementia and its
subtype is of importance; however, it remains clinically challenging. Improved differentiation is critical,
as misdiagnosis can lead to incorrect treatment and management of disease [133]. This is particularly
pronounced between LBD and AD due to shared clinical features and cross-pathology [134–136]. DLB is
pathologically classified by the presence of Lewy bodies containing abnormally folded alpha-synuclein
within the brain. Clinically, it is differentiated from AD by prominent deficits in attention, visuospatial
and executive function, cognitive fluctuations, visual hallucinations, RBD, and parkinsonism [133].
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Gait, rather than being an autonomous task, is under cognitive control due to shared neural
networks, and is evident in dementia cohorts [137]. Slow gait precedes and predicts cognitive decline
and dementia, with gait impairments occurring up to nine years prior to diagnosis [138]. Even in the
early stages of cognitive impairment, people with MCI walk slower, with shorter steps and increased
variability compared to cognitively intact older adults [139,140]. People with dementia walk slower,
with shorter strides and increased stride time variability compared to controls, and this increases with
disease severity [140–144]. A recent review of gait across common dementia subtypes revealed slower
gait and impaired timing (i.e., longer stance, stride, double support time) in people with AD, LBD, and
VaD compared to controls [145–148], and demonstrated some evidence for a greater variability of gait
in people with AD [149–153]. Falls risk is also increased in dementia and MCI, with DLB and PDD
subtypes reporting the greatest risk [154]. An important link has been demonstrated in those with
preclinical AD and falls, highlighting a possible underlying pathological basis, as amyloid burden
predicted falls risk [155]. Discrete gait characteristics may serve as a useful tool for distinguishing
between dementia subtypes [31], and can thus aid diagnosis. Differences between subtypes include
slower gait in VaD compared to AD and slower pace, impaired timing, and an increased variability of
gait in LBD compared to AD [145]. There is evidence to suggest that gait impairments differ across MCI
subtypes [153], supporting a role for discrete gait outcomes as clinical biomarkers to aid diagnosis.
Only a small number of studies have looked at postural control in older adults with cognitive
impairment, making it difficult to draw robust conclusions. A recent review reported impaired postural
control in MCI [139] and AD [156]. However, group differences are not consistent [156]. More research
may demonstrate postural control assessment, in addition to gait analysis, as a useful biomarker of
cognitive impairment.
More recently, the monitoring of gait using body-worn sensors as in other neurological diseases
has been explored in people with dementia. A recent study showed that clinic and home-based
monitoring was feasible and acceptable in dementia populations, and trends suggest that gait
impairments such as greater variability and a slower pace can differentiate dementia from controls
when measured in free-living environments [157,158]. This shows potential use for monitoring gait
prior to dementia onset and throughout the progression of the disease, providing valuable insight into
the utility of gait as a clinical tool for the diagnosis and monitoring of dementia.
3.4. Summary
The current literature suggests that measuring gait and postural control has utility as a clinical tool,
both for supporting diagnosis and monitoring disease progression. Impairments in gait and postural
control may be the first manifestation of underlying neurological disease, such as in Parkinson’s disease,
ataxia, and dementia. There is evidence for the role of gait analysis in predicting and identifying the
onset of cognitive decline in Parkinson’s disease, and emerging evidence for the use of gait as a possible
biomarker of dementia subtype. The early accurate diagnosis of these neurodegenerative conditions is
a key target within clinical research, and the recent emergence of inexpensive wearable technology for
analysing gait and posture has potential to be deployed as a widespread diagnostic tool. Quantifying
gait and postural deficits can also be informative towards fall risk, which is a common problem in
neurological conditions. Gait and postural measurements are increasingly used for disease progression
monitoring, and may form an important part of a digital endpoint in clinical trials. Wearable technology
and quantitative clinical measures may lead to improvements in the accurate identification of diagnosis,
and may highlight individuals who would benefit from targeted intervention. Lastly, there is the
opportunity to combine movement-based measures with biochemical and genetic analysis, such as in
PD, where carriers of the autosomal dominant G2019S showed significant changes in gait variability
compared to non-carriers [159].
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4. Section III: Emerging Techniques for Disease Classification and Risk Prediction—So-Called
‘Big Data’ Approaches
It is evident that there is a plethora of measurement outcomes that are used to describe gait and
postural control that are often used generally across a range of neurological conditions. Typically,
a univariate approach is adopted, whereby measurement outcomes are considered independently,
which may increase the risk of losing important information. Developing methods to reduce the
number of (gait or postural) measurement outcomes included within statistical models is needed.
Data-driven approaches that apply machine learning principles are beginning to explore the optimal
combination of characteristics that successfully classify patients by condition (Figure 2) to improve
diagnostic accuracy [160]. Recent work has used gait characteristics for fall classification in people
with PD [161], and sensitivity analysis for feature selection when classifying PD [162]. A variety of
data mining and machine learning approaches have been used to classify neurological conditions
using gait and postural control data. For example, support vector machine techniques identified
patients in the early stages of PD using their step length, which was measured during gait [163].
Multiple layer perception neural networks have distinguished Friedrich’s ataxia from controls using
stride time and gyroscope-derived outcomes [164]. Postural control measures have demonstrated
utility for distinguishing AD from controls [165]. Adopting these analytical approaches also allow
for gait and postural control outcomes to be considered in combination rather than independently.
However, further research is required to select the appropriate gait and postural control characteristics
for each disease type. This will aid clinical interpretation, reduce computational demand, and improve
classification accuracy [12,166].
Realistically, in the future, wearable sensors will be the most practical tool to use to capture
gait and postural control. However, gait and postural control data derived from wearable sensors is
complex, multidimensional, and has high patient variability (no two patients are alike). Therefore,
there is a need to find measures that offer increased sensitivity for distinguishing between neurological
conditions at each disease severity level while controlling for between-person variability. Promising
attempts to model and classify dementia and PD using measures of gait and postural control with a
variety of classification tools (e.g., support vector machines, hidden Markov models, multilayer layer
perception, neural networks, etc.) have been reported [163–165,167–171]. Even though the perfect
classification accuracy is reported with various techniques, the optimal method or combination of
approaches has not been identified, much less tested. In addition, robust modelling has not been
possible, because studies are often limited to data collected in small, poorly described patient cohorts.
Efficient systems for computational processing, the visualisation of multivariate gait and postural
control profiles, and disease modelling in a clinician-friendly format are also essential for clinical
adoption. There are currently no established tools for identifying and detecting disease or modelling
disease progression in neurological diseases such as those described in this review. This is currently an
area of significant interest.
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Figure 2. A machine learning end-to-end framework for the analysis of gait dynamics in the laboratory
and community.
5. Section IV: Recommendations and Future Direction
A growing interest and body of literature is evident in the area of gait and postural control
measurement. Complex techniques such as motion capture are unlikely to be deployed in clinical
settings on a large scale in their present form due to their considerable cost, the dedicated
personnel/expertise required, and potentially lengthy data collection and analysis period. However,
techniques that reduce participant preparation time are currently being developed (i.e., markerless
motion capture [172–174]) and aim to drive down financial cost, improve accessibility, reduce data
collection time, and ultimately increase productivity. Although showing promise, similar to wearable
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sensors, research into the accuracy and validity of each device is paramount before integration in
routine clinical practice. Furthermore, continued research should strive towards continued algorithm
development to provide the most robust sensitive measures to clinicians so as to overcome the current
pitfalls of the technology. The ultimate goal of community-based methods to quantify gait and postural
control is to characterise clinical populations on a global scale and revolutionise current healthcare
practises. Remote monitoring offers the opportunity to put the patient at the forefront of his or her
own healthcare and management, and provide timely and effective intervention. First, to achieve
such progress, it is imperative to ensure that the platform (device, outcomes, protocols, analytical
pipelines, and processes) for collecting this information is robust, and personal data remains secure.
This will allow the creation of normative databases, increasing prognostic capacity and providing
a comprehensive understanding of the clinical landscape and therapeutic needs. Novel therapeutic
interventions are required that are personalised, targeted to specific gait and postural impairments,
and ultimately effective.
Future challenges include disentangling the process of ageing from the accelerated process of
neurodegeneration whilst accounting for individual variation, comorbidities, lifestyle, overlapping
sequelae, and atypical disorders, etc. To achieve this goal, the investigation of deep/machine learning
techniques that have the potential to include other non-movement analysis-derived biomarkers
appears to be a worthy pursuit. As such, more epidemiological studies are required to understand
the interaction between lifestyle factors, individual capacity, and the environment [175] to improve
prognostic and diagnostic accuracy. Collecting and aligning prodromal and disease cohort studies
through dedicated consortia will enrich our current understanding of biomarkers and risk factors.
Incorporating post mortem data retrospectively would be beneficial to verify the underlying pathology
in complex conditions.
Recommendations
• Quantitative, objective assessments of gait and postural control should supplement traditional
disease-specific scales in clinical trials to aid diagnostic accuracy and patient monitoring.
• Education around the advantages and disadvantages of quantitative analysis should be available
to allow the clinician and clinical academic to make an informed decision about the best tool,
protocol, and outcomes.
• Continued efforts are needed to validate the optimal protocol and outcome measures to best
inform clinical management and research, and this requires a discrete condition-based approach.
• Further research using machine/deep learning should be explored to advance opportunities for
optimised diagnosis and disease monitoring.
• Development of normative values across a range of standardised outcomes will help interpret
gait and postural control outcome measures, and embed their clinical use and a personalised
approach to management.
• Further research is needed in order to validate gait and postural control as approved disease
biomarkers and progression markers.
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Abstract: In the last years, lysosomal storage diseases appear as a bridge of knowledge between
rare genetic inborn metabolic disorders and neurodegenerative diseases such as Parkinson’s disease
(PD) or frontotemporal dementia. Epidemiological studies helped promote research in the field that
continues to improve our understanding of the link between mutations in the glucocerebrosidase
(GBA) gene and PD. We conducted a review of this link, highlighting the association in GBA mutation
carriers and in Gaucher disease type 1 patients (GD type 1). A comprehensive review of the literature
from January 2008 to December 2018 was undertaken. Relevance findings include: (1) There
is a bidirectional interaction between GBA and α- synuclein in protein homeostasis regulatory
pathways involving the clearance of aggregated proteins. (2) The link between GBA deficiency
and PD appears not to be restricted to α–synuclein aggregates but also involves Parkin and PINK1
mutations. (3) Other factors help explain this association, including early and later endosomes and
the lysosomal-associated membrane protein 2A (LAMP-2A) involved in the chaperone-mediated
autophagy (CMA). (4) The best knowledge allows researchers to explore new therapeutic pathways
alongside substrate reduction or enzyme replacement therapies.
Keywords: glucocerebrosidase; Parkinson’s disease; Gaucher disease
1. Introduction
In the past decade, advances in the knowledge of the pathophysiological process of Parkinson’s
disease (PD) have shed light on the comprehensive mechanisms involved in protein accumulation and
aggregation in neurodegenerative diseases [1–3].
Parkinson’s is the second most common neurodegenerative disorder. Criteria for diagnosis were
redefined in 2015 by Postuma et al., with multiple genes identified as causative or as an increased risk
factor [2].
In PD, a complex underlying physiopathology involving molecular processes results in alpha
synuclein (α-syn) misfolding, leading abnormal aggregation and the accumulation of insoluble α-syn.
A key player in this matter is the lysosomal-autophagy system (LAS), being an important target
for many new therapeutic targets in current clinical trials [1].
New genetic findings help support a concomitant dysfunctional proteostasis involving several
systems, including the ubiquitin–proteasome system (UPS), chaperones, and the LAS [1,4,5].
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The major candidate gene involved in PD with autosomal dominant inheritance are leucine-rich
repeat kinase 2 (LRRK2), alpha-synuclein (SNCA), vacuolar sorting protein 35 (VPS35), and DnaJ
homolog subfamily C member 13 (DNAJC13). In the recessive pattern the major genes players are
Parkin, PINK1, and DJ1, as well as GBA [6–8].
Although the understanding of these gene functions is incomplete, several of them are involved
in different protein and organelle clearance pathways.
In this sense, the homeostasis of α-synuclein depends on the ubiquitin–proteasome system
(UBQ-PS) and the LAS that comprise the chaperone-mediated autophagy and macroautophagy [9].
The SNCA mutations and multiplications promote the accumulation of α-synuclein oligomers
inhibiting the UBQ-PS and macroautophagy.
The LRRK2 gene encodes a kinase with a protein–protein interaction, involved in transcription,
translation, or apoptotic processes, and in membrane trafficking and cytoskeletal function [10].
The LRRK2 and G2019S mutations have been reported to be associated with LAS and mitochondrial
impairments probably mediated by a gain-of-function effect.
In the same way, deficiency and mutations in VPS35 (the encoded protein is involved in the
retromer complex) not only act in the recycling of membrane proteins via retrograde transport from
endosomes back to the trans-Golgi (endosome-to-Golgi retrieval) but also have been associated with
decreased cellular levels of the lysosome-associated membrane glycoprotein 2A (LAMP-2A), a protein
membrane involved in lysosome translocation, affecting once again the LAS [11].
Among the recessive genes linked to PD, proteins encoded by PARK2 and PINK1 cooperate in the
clearance of damaged mitochondria through mitophagy. Impaired degradation of MIRO (a protein in
the outer mitochondrial membrane that connects the organelle to microtubule motors) seems to have a
role in defective clearance of damaged mitochondria [6–8].
Parkin is an E3 ubiquitin ligase protein, catalyzing the transfer of ubiquitin to its specific target
protein; PINK1 is a mitochondrial kinase that localizes to damaged mitochondria and recruits Parkin
in the outer mitochondrial membrane to initiate polyubiquitination of mitofusins for fusion and fission
of damaged mitochondria or clearance by UBQ-PS or autophagy involving, again, the LAS [12].
Inborn errors of metabolism (IEM) are characterized by mutations in genes coding enzymes
involved in different metabolic pathways. Lysosomal diseases enclose an extensive number of genetic
disorders characterized by malfunction of the lysosomal enzymes in the LAS [13,14].
Gaucher disease (GD) is the most frequent lysosomal storage disease inherited in an autosomal
recessive pattern [4,15,16]. More than 300 different mutations of the glucocerebrosidase 1 (GBA1)
gene have been described, with over 12 different genotypes. This gene is located on chromosome 1q2
and encodes glucocerebrosidase (GCase). The GCase enzyme catalyzes the hydrolysis of glycolipid
glucocerebroside to ceramide and glucose [17]. It is synthesized in the endoplasmic reticulum (ER)
and transported to lysosomes via lysosomal membrane protein 2 (LIMP2). The binding of GCase to
LIMP2 is facilitated by the neutral pH of the ER. These proteins remain together at the Golgi apparatus
and endosomes, but their dissociation is facilitated by acidic pH into the lysosome [18,19].
Glucocerebroside accumulation results in a systemic disease with distinctive phenotypes [4].
The clinical classification describes three different subtypes, GD 1, 2, and 3, respectively [13,20].
Type 2 or acute neuronopathic is the more severe phenotype and is beyond the scope of the
present review, affecting perinatal and infancy with a severe prognosis and limited survival of no more
than 3 years, with severe ocular abnormalities, development delay and brainstem involvement and
severe hematological and visceral compromise.
Gaucher disease type 3 is called subacute neuronopathic variant with age at onset in childhood
with neurological involvement including oculomotor abnormalities, ataxia, seizures (myoclonic
epilepsy) and dementia.
Finally, GD type 1 is classically mentioned as non-neuronopathic, with a wide spectrum of age at
onset, anemia, thrombocytopenia, and enlargement of the spleen, skeletal abnormalities, interstitial
disease and pulmonary hypertension. However, it has been estimated that a neurological symptom
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occurs in 50% of patients with GD1, and it is possible to identify a neurological abnormality during
examination in 30% of patients without neurological complaints [21–23].
Epidemiological studies in GD type 1 showed an association between GCase deficiency and
Parkinsonism. In fact, the homozygous and heterozygous mutations, constitute a strongest risk factor
for the development of PD and Lewy Body Dementia (LBP) [4].
This review primarily focuses on the potential link between GCase deficiency and PD and
identifies new potential common pharmacological approaches to GD, a rare treatable disorder, and
PD [24].
2. Methods
2.1. Search Strategy and Selection Criteria
A literature search was conducted to identify relevant articles published in English, based
on Medline (via Pubmed) from January 2008 to December 2018. One local article in Spanish was
included [25].
2.2. Lysosomal Diseases and Gaucher Epidemiology
Several movement disorders have been described in the spectrum of lysosomal diseases,
among them levodopa responsive parkinsonism and parkinsonism plus (ataxia, dystonia or
spasticity) [4,13,21,26]. In this sense, GBA mutation, neuronal ceroid lipofuscinosis, Kufor–Rakeb
disease, Niemann Pick type C are among the lysosomal disorders associated to hypokinetic movement
disorders and more specifically to Parkinsonisms [21].
In a recent study of a cohort of 76 individuals with different lysosomal diseases, GD was identified
in 3.99% of them [26].
Among the conferred risk of genes and genetic loci associated with the development of idiopathic
PD, it was observed that GBA mutations are the most common genetic risk factor for developing
PD [27,28]. Furthermore, GD patients and GBA mutation carriers are at higher risk of developing
parkinsonism. Large epidemiological studies found that GBA mutations were significantly prevalent in
PD patients (Odd Ratio: 5.43); between 5% and 20% of all PD patients have a GBA mutation [4,29–31].
Further, GBA1 mutations are the most common genetic risk factor for developing PD [27].
The worldwide range of prevalence of GD type 1 has been estimated at between 1:40,000 and
1:60,000, with the highest prevalence in Ashkenazi Jews (1:850) [32] (19.20%), intermediated
prevalence in the North American population (12.93%–15.90%), and lowest in the Asian population
(2.70%–3.70%) [27,33–46]. This association is stronger for dementia with Lewy bodies (LBD).
Epidemiological data suggest that non-neuropathic GD type 1 needs to be redefined, taking into
account the occurrence of neurological signs and symptoms such as movement disorders, cognitive
decline, slow saccades and progressive supranuclear palsy [21,47].
2.3. Phenotype/Genotype: Clinical Features
From a clinical point of view, some differences arise between idiopathic PD and GBA mutated
carriers (GBAmtt carriers) with PD. For instance, PD-GBA carriers tend to have a younger age at
onset. A good response to l-dopa is a common finding; however, there is contrasting evidence for the
occurrence of levodopa-induced dyskinesias, and in those cases the risk is related to the age at onset.
Non-motor symptoms, autonomic dysfunction (including enteric, sexual and urinary dysfunctions
as well as orthostatic hypotension), fatigue, anxiety, pain, REM behavior disorders (RBD) and cognitive
impairment are more frequent in GBAmtt carriers than in individuals with idiopathic Parkinsonism.
A multi-domain impairment has been reported involving memory, visuospatial, abstraction,
orientation, working memory, executive, visuospatial abilities and visual short-term memory.
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Mood, behavioral and psychiatric symptoms appear as a common manifestation in GBA-PD,
with earlier development of psychosis and hallucinations, as well as higher prevalence of depression,
apathy and anxiety [4,48].
2.4. Biomarkers
Clinical and neuroimaging biomarkers in GBAmtt carriers with PD with respect to the idiopathic
PD (iPD) patients are presented in Table 1.
Table 1. Clinical and neuroimaging potential biomarkers of Gaucher disease (GD) type 1.
Biomarker Observation References
Clinical biomarker Early multidomain cognitive impairment.More severe Levodopa induced dyskinesias.
Transcranial sonography Nigral hyperechogenicity. [49]
PET 1 8F dopa Decreased striatal dopamine synthesis, similar to iPD.Bilateral asymmetric reduction in striatal uptake. [50,51]
fMRI
Significant hypometabolism in glucose metabolism in
supplementary motor area and parieto-occipital cortices.
Hypermetabolism of the lentiform nuclei and thalamus.




Decreased frontal cortico-cortical and parahippocampal
tracts in GBA-PD.
Decreased fractional anisotropy of the corpus callosum,
olfactory tract, anterior limb of the internal capsule,





Postsynaptic dopamine terminal persistence of higher
putaminal uptake in advanced disease. [53]
GD: Gaucher Disease. PET: Positron Emission Tomography. GD-PD: Gaucher Disease–Parkinson Disease.
iPD: idiopathic Parkinson Disease. fMRI: functional magnetic resonance imaging. MRI: magnetic resonance
imaging. DA: dopamine.
2.4.1. Wet Biomarkers in GBA Mutation Carriers PD
Dried blood spot and cerebrospinal fluid (CSF) studies demonstrated a decreased
glucocerebrosidase (GCase) activity in PD patients with and without GBA mutation carriers versus
healthy controls. The decreased activity correlates with a worse cognitive performance [54–56].
2.4.2. Prodromal Signs in PD-GBA Patients
As in iPD, prodromal signs have been described in GD type 1 patients and GBA mtt carriers.
Hyposmia, cognitive dysfunction (involvement of attention, working memory and speed of memory),
subtle motor signs, depression, smell and autonomic dysfunction were more common in GBA patients
and carriers. Thus, these are suggested as potential neurodegeneration markers in GD patients and
carriers [35,47].
Gatto et al. conducted a study in the city of Buenos Aires, Argentina where prodromal clinical
markers of PD were explored in GD patients [57]. A total of 26 patients with GD1 were included, and
all of them were under enzymatic replacement therapy. Questionnaires used to identify non-motor
PD symptoms revealed that 26.9% had parasomnias, 7.69% RBD and constipation, 3.84% hyposmia
and 11.53% depression. Some 44.4% had some degree of cognitive impairment. Although none of
the patients studied fulfilled Queen Square Brain Bank criteria for PD, the presence of non-motor
symptoms, as in other series, could be used as potential prodromic biomarkers for Parkinsonism [57].
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2.4.3. Cognition in GBA Homozygous and Heterozygous GBA Mutations Carriers
Although data on cognition in asymptomatic GBA mutation carriers are scarce, several authors
found substantially increased risk of conversion to dementia in GBA mutations carriers [58].
GD type1 and GBA mtt carriers were associated with an earlier age at onset of PD and a higher
MDS-UPDRS III, associated with attention, working memory and speed memory impairment. In these
cases, the cognitive decline represents one of the most debilitating manifestation impairing the quality
of life [59]).
Genetic factors could contribute to modulate the risk of PD and dementia in GBA carriers.
For instance, null/severe L444P mutations have the highest risk, while an intermediate risk has
been reported for mild mutations such as N370S, and the lowest risk was associated with a
E326K polymorphism.
In a study conducted by Mata et al. in 2016 [60], the authors found that pathogenic mutations
and the E326K polymorphism within the GBA gene were associated with a higher prevalence of
dementia involving working memory/executive function and visuospatial abilities. These results
suggest that even homozygous carriers for E326K polymorphism do not develop GD; this single
nucleotide polymorphism might influence the risk of PD cognitive dysfunction.
Controversial results were reported when the LRRK2 and GBA gene mutation carrier cohorts were
compared. Some authors failed to identify any cognitive difference in asymptomatic GBA and LRRK2
mutation carriers [61], whereas others identified a lower mean MoCA score and a worsening verbal
memory in non-manifesting LRRK2 carriers with respect to the GBA mutations carriers [62]. It remains
under discussion whether a more diffuse and extensive neocortical Lewy body pathology increases
the risk of cognitive dysfunction in homozygous and heterozygous GBA mtt carriers. However, only a
marginal difference was found in a PD clinic pathological study performed in GBA mutation carriers
and non-carriers.
Finally, as in iPD, depression in GBA carriers appears as a prodromal factor influencing the
performance in cognitive testing.
2.4.4. The Role of Autophagy in Lysosomal Diseases and Neurodegeneration (α-synuclein)
An extensive number of experimental studies showed that GBA can stabilize α-synuclein
oligomers which in turn inhibit GBA function, causing glycocylceramide (GlcCer) accumulation
and further attenuate α-synuclein aggregation [63].
Under normal conditions, the autophagy system allows the cell to degrade different compounds.
The different types of autophagy are: Microautophagy, macroautophagy and chaperone-mediated
autophagy (CMA). These are carried out differently, but the final common pathway is the lysosome,
a key player in proteins, lipids and organelles degradation [64,65].
We make a special note of alpha synuclein (α-syn), α-syn is a presynaptic protein, involved in
neurotransmitter release through the SNARE complex. When an impairment in the degradation of
α-syn occurs, this protein accumulates as insoluble fibrils, giving rise to toxicity in multiple cellular
processes (lysosome, mitochondria, proteasome and cellular membrane recycle) [66,67].
It is thought that this accumulation is derived from Lewy body pathology. However, some
authors propose a protective cycle through protein accumulation mediated by α-syn. Interestingly,
α-syn accumulation leads to reduced GCase and GCase accumulation makes the cell prone to α-syn
deposition. Thus, this pathological cycle between GCase and α-syn worsens the condition [4,29].
Cellular protein accumulation promotes what is known as endoplasmic reticulum stress (ERS).
When activated, it leads to an apoptotic pathway. Moreover, when ERS is activated there is an inhibition
of other ER substrates as well as malfunction of Golgi traffic. This process has also been observed in
PD patients with PARK2 mutations, thus suggesting that ERS has a role in PD pathology [4,29].
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2.4.5. GBA Gene Mutations
Next-generation sequencing technologies have had a dramatic impact on the field of genomic
research and on knowledge of GBA mutations. This autosomal recessive disease is caused by different
mutations in the GBA gene that encode lysosomal enzyme glucocerebrosidase (Gcase), (in chromosome
1q21 [68]). This gene contains 11 exons and 10 introns, covering 7.6 kilobases (kb) of sequence. Over
300 mutations, including point mutations, insertions, deletions and frameshift mutations, in the GBA
gene have been identified; seven of them account for approximately 96% of the mutant alleles in
Ashkenazi Jews (AJ). The most common mutations are: K198T, E326K, T369M, N370S, V394L, D409H,
L444P, and R496H. Both N370S and R496H are considered mild mutations, whereas E326K, N370S,
and L444P are associated with severe neuronopathic forms of GD. The most deleterious is considered
to be L44P, causing high protein destabilization, related to its position at the beginning of the beta
sheet [4,16,68,69].
The most common mutation in the GBA gene worldwide is N370S/N370S, followed by
N370S/L444P [70]. Severe GBA mutations (L444P) cause neuronopathic GD onset during infancy and
childhood, rapid progression, severe neurological symptoms and shorter life expectancy. Mild GD is
caused by N370S mutations; interestingly over 50% of GD-PD are homozygous for these mutations, and
90% of these patients carry at least one N370S mutation. This is important to take into consideration
for carriers of GBA mutations where severe mutations are related to a higher risk of developing PD7.
Moreover, mutations in GBA coding for pathogenic neuropathic GD and heterozygous severe forms
accelerate cognitive decline in these patients [71].
The increased PD risk in GBA mutation carriers is racially dependent. The analysis in AJ
population identified 84 insGG and R496H variants as the exclusive risk for increased PD in this
population, whereas, in non-AJ, L444P, R120W, IVS2+1G > A, H255Q, D409H, RecNciI, E326K, and
T369M represent the highest risk variants with an ethnic distribution. The N370S appears as a risk
variant of PD in AJ and non-AJ populations, while L444P increased the risk of PD in all groups
in non-AJ ethnicity [72]. Other variants, including N370S, H255Q, D409H and E326K, exclusively
increased PD risk in non-AJ European/West Asians, whereas R120W increased PD risk in East Asians.
The polymorphic variant E326K represents an interesting variant to analyze, taking into account
that controversial results have been reported regarding the risk of PD. A recent meta-analysis reveals
that E326K of GBA is associated with a risk of PD in total populations, Asians and Caucasians [73,74].
In the Argentinean GD population, the prevalent variants were: Genotype N307S/other allele
(82.5%), N307S/L444P and N307S/N307S [25].
A correlation genotype/phenotype is presented in Table 2.
Table 2. Phenotype/genotype correlation.
Null or Severe GBAmtt Mild GD
L444P N307S
Phenotype
Onset infancy and childhood, rapid
progression shorter life expectancy, and
appearance of more severe neurologic
features (GD2, GD3)
50% GD-PD homozygous for N307S
90% GD-PD carry at least one N307S
mutation
For GBA mutation carriers, “severe” mutations have a higher risk of Parkinson’s disease (PD) than “mild mutations,”
as well as early age onset of symptoms, initial bradykinesia and family history of dementia [14,62]. GD: Gaucher
disease. GBA: glucocerebrosidase. GD-PD: Gaucher-DiseaseParkinson Disease.
2.5. Gaucher and PD: the Ethiopatogenic Link
Parkinson’s disease is the second most common neurodegenerative disorder worldwide. Multiple
pathways for cortical and subcortical structures are involved in the pathology. The hallmark for PD is
the intracellular aggregation of α-synuclein. As discussed earlier, PD emerges as a consequence of
the failure of multiple cellular pathways to avoid damage by toxic protein accumulation. The failure
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of protein homeostasis leads to dysfunction of the two major catabolic pathways, UPS, and the
autophagy-lysosomal pathway (ALP), as well as mitochondrial, ER and vesicular transport [75,76].
Alpha-synuclein constitutes the major component of LB. It has been proposed that LB deposition
follows a sequential pattern of accumulation, as proposed by Braak et al. in 2003 [77]. Initially
affecting the dorsal nucleus of the glossopharyngeal and vagal nerves, brainstem, mesocortex and
lastly neocortex [4].
Early studies demonstrated a colocalization of mutant GCase in LB and Lewy neuritis (LN) in
subjects carrying GBA.
Moreover, several recent studies have shown that the levels of GCase catalytic activity is reduced
in GBA homozygous and heterozygous carriers as well as mRNA GCase levels. The decreased GCase
activity was not restricted to GBA carriers but was also identified in iPD and DLB, with a marked
distribution in different brain areas and more pronounced in Substantia Nigra (SN) [1].
The decrease of GCase activity correlates with GBA post translational regulators, protein
interactors, lysosomal integral membrane protein 2 (LIMP-2) and saposin C (SapC) [1].
Several GCase mutations, including N370S and L444P, unfold in the ER, activating the unfolded
protein response (UPR).
Pathways of GCase from the ER to the lysosome in wild and mutant GCase are presented in
Figure 1.
Figure 1. Glucocerebrosidase pathway: Black circles represent wild-type glucocerebrosidase (wtCGase)
that is produced in the endoplasmic reticulum (ER), glycosylated in the Golgi, and is translocated
to the lysosome in a LIMP-2 dependent process, where it degrades glucosylceramide substrates.
Red circles represent mutant enzyme (mttGCase), not folded correctly and inducing the ER stress
response. This ER stress response comprises: The ER-associated protein degradation (ERAD) that
re-translocated mttGCase from the ER to the cytoplasm and unfolded protein response (UPR) in an
attempt to re-establish homeostasis via ubiquitin proteasome system (UBQ-PS), cytosolic chaperone
complex (CMA) represents another pathway to refold mttGCase by hsc70 linked to the LAMP-2A to
deliver the protein to the lysosome. The dotted line represents the small fraction of mttGCase that
could take the normal pathway.
Mutant GCase (mtt GCase) leads to ER stress (ERAD), inducement of UPR, proteosomal
breakdown by UBQ-PS, cytoplasmic chaperone-mediated autophagy (CMA), delivery of unfolded
proteins into the lysosome by chaperones, and the involvement of LAMP-2A, a protein membrane,
in translocation. Glycocylceramide accumulates in the lysosome. Macroautophagy is involved in the
degradation of damaged organelles and aggregated proteins and modified lipids [78].
The GCase needs to interact at the ER with LIMP-2 to be glycosylated and transported to lysosome
to exert hydrolytic activity on GlcCer [79].
42
Brain Sci. 2019, 9, 30
2.6. α-Synuclein and GCase Link
The PD pathophysiologic mechanisms are very complex, involving several pathways related to
a failure of α-synuclein degradation, oxidative stress, neuroinflammation, and mitochondrial and
synaptic dysfunction. Ubiquitin proteasome dysfunction, macroautophagy and CMA impairment
promote α-synuclein aggregation and a prion-like transmission.
Both PD and GD share pathological processes that result in lysosomal dysfunction, dysfunctional
lipid metabolism, prion-like transmission and bidirectional feedback loop. As a result of the incomplete
clearance of these substrates, in GBA-PD, a decrease in GCase activity results in increased levels of
glucosylceramide, affecting autophagy and promoting α-synuclein accumulation by stabilization
of α-synuclein oligomeric forms [80]. High levels of intracellular α-synuclein prones subsequent
ERAD and contributes to GCase glycosylation as well as trafficking dysfunction from ER to Golgi and
finally to lysosomes. This pathological loop enhances, so accumulation of glucosylceramide causes
α-synuclein, and high α-synuclein levels inhibit GCase. The final consequence is a loss of lysosomal
activity and neuronal death [4,81].
Recently, Thomas et al. [82] identified a membrane lipid composition alteration in Drosophila
mutants with deletions in the GBA ortholog Gba1b. This membrane alteration increases the formation
and release of extracellular vesicles that might lead to aggregates seeding and spread cell-to-cell
neurodegeneration as a major mechanism for the association of GBA and PD neurodegeneration.
2.7. Parkin-Pink1 Mitochondria and GCase
Dysfunctional mitochondria and failure in mitophagy (macroautophagy) have been identified in
brain tissues from GBA-PD patients and GBAL444P.
Furthermore, SNCA, PINK1 and PRKN, PARK7 and LRRK2 have a role in the equilibrium between
mitochondrial fusion and fission [83–89].
Li et al. reported, in an experimental model of GBA-PD, two mechanisms affecting mitochondria:
(a) The impairment of autophagy secondary to lysosomal accumulation of glucosylceramide with
decreased GBA activity, and (b) mitochondrial priming, with decreased mitochondrial fission [88,90].
The mitochondrial priming represents the PINK1-PARK2 pathway required for the balance
between fusion and fission [88].
The interaction between Parkin2 and GBA is restricted not only to mitochondrial involvement
but also by competitive ubiquitination of mutant GCase, promoting protein accumulation, leading
ERAD, increasing cytosolic Ca2+ and apoptosis [89].
2.8. Therapeutic Implications
Amongst the treatment strategies in patients with GD, either substrate reduction therapy (SRT) or
enzyme replacement therapy (ERT) is traditionally employed. For the former, the target is to inhibit
glucosylceramide synthase.
When considering ERT, imiglucerase (effective for GD1 patients), velaglucerase alfa and
taliglucerase alfa are the available options. None of these is able to cross the blood–brain barrier
(BBB), being ineffective in neurological symptoms [4].
Substrate reduction therapy is considered second in line for the treatment of GD, because of
its adverse events. Some drugs are able to cross the BBB, such as miglustat, a small iminosugar
with reversible inhibitor activity. It was thought that it could be useful for GD3 patients; however,
a randomized study did not prove significant difference in the patients in terms of neurological
symptoms [4,91].
Due to the relationship between GCase and α-synuclein deposition, new promising therapies
are under investigation for patients with PD and GBA mutations. In this matter, the MOVES-PD
trial has been announced, in which GZ/SAR402671 will be tested in PD patients with a single GBA
mutation in order to reduce the production of glycosphingolipids [92]. On this point, Sardi et al. [93]
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showed, in experimental models, that α-syn accumulation could be reduced using a glycosylceramide
synthase inhibitor (GCC) called Venglustat. It was demonstrated that GCC could reduce the levels
of glycosylceramide in the central nervous system (CNS), reduce the accumulation of α -syn in the
hippocampus and ameliorate cognitive deficits, making this a promising disease-modifying therapy.
2.9. Future Therapies for GD
Due to the multiple cellular pathways involved in GD, other therapies that target different sites
of these pathways are under investigation. Chaperones are small molecules that facilitate the correct
folding and translocation of GCase, hence making them a suitable option for treating lysosomal
disorders. An example of this is ambroxol (ABX).
Chaperones bind to misfolded GCase and cross BBB. Ambroxol acts as a pharmacological
chaperone, enhancing lysosomal function and autophagy. It has been shown that ABX significantly
increases glycosylceramidase and reduces α-syn, especially in the striatum. Antioxidative functions
of ABX have also been postulated as an important property [29,94]. A novel non-inhibitory GCase
chaperone, NCGC607, restored the levels of GCase activity and reduced α-syn levels in dopaminergic
neurons [95].
Other therapies included histone deacetylase inhibitor, promoting the activity of the mutant
GCase [96]. Also, lentiviral vectors with cellular promoters may play a role in future clinical
gene therapy protocols for GD1 [96]. Autophagy enhancement through the mTor-pathway, using
rapamycins, has been shown to reduce α-synuclein aggregation [4].
Recently, Zunke et al. [97] demonstrated that accumulation of glycosphingolipids in GD promote
conformational changes in α-synuclein-leading aggregation and toxicity. In this scenario the reduction
of glycosphingolipids appears as a potential new therapeutic pathway, taking into account the fact
that this reduction was able to reduce pathology and reverse α-synuclein to the normal conformation
in carrier and non-carrier PD patients.
More recently, Kim et al. [98] suggested a new therapeutic approach by inhibition of acid
ceramidase. This inhibition helps increase the ceramide levels in lysosome in GCase mutant cells and
reduce α-synuclein accumulation.
3. Conclusions
As previously mentioned, GBA mutations are the most common genetic risk factors associated
with PD, especially common in AJ populations. Multiple cellular pathways are linked to GD. This
includes lysosomal dysfunction, ERS, autophagy and α-syn deposition, each of them enhancing a
vicious cycle of more protein misfolding and deposition. As proposed by Espay et al. [99]. Parkinson’s
disease could be considered as a group of disorders that share nigral dopamine-neuron degeneration;
hence, PD is divided into different subgroups of PD with their own distinctive biology. This could
be useful in the development of disease-modifying therapies for each subgroup of targeted patients.
Parkinson’s disease in GD patients could be a subgroup of patients for whom disease-modifying
therapies that reduce α-syn and slow, reduce or even stop disease progression could be effective. More
clinical trials are required in order to analyze these patients.
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Abstract: Genetics has led to a new focus regarding approaches to the most prevalent diseases
today. Ascertaining the molecular secrets of neurodegenerative diseases will lead to developing
drugs that will change natural history, thereby affecting the quality of life and mortality of patients.
The sequencing of candidate genes in patients suffering neurodegenerative pathologies is faster,
more accurate, and has a lower cost, thereby enabling algorithms to be proposed regarding the risk
of neurodegeneration onset in healthy persons including the year of onset and neurodegeneration
severity. Next generation sequencing has resulted in an explosion of articles regarding the diagnosis of
neurodegenerative diseases involving exome sequencing or sequencing a whole gene for correlating
phenotypical expression with genetic mutations in proteins having key functions. Many of them
occur in neuronal glia, which can trigger a proinflammatory effect leading to defective proteins
causing sporadic or familial mutations. This article reviews the genetic diagnosis techniques and the
importance of bioinformatics in interpreting results from neurodegenerative diseases. Risk scores
must be established in the near future regarding diseases with a high incidence in healthy people for
defining prevention strategies or an early start for giving drugs in the absence of symptoms.
Keywords: genetic biomarker; Parkinson’s disease (PD); Alzheimer’s disease (AD); next generation
sequencing (NGS); diagnosis; neurodegenerative disease; amyotrophic lateral sclerosis (ALS)
1. Introduction
Advances have been made regarding chronic disease therapy due to an understanding of
altered molecular mechanisms in cells from different bodily organs. One of the most fascinating
advances during the last decade has occurred in the field of genetics concerning new sequencing
techniques; this concerns identifying genotypic aberrations leading to the determination dysfunctional
phenotypic expressions using large bioinformatic databases. Sequencing a genome or exome for
clinical applications has now entered medical practice. Several thousand tests have already been
ordered for patients to establish a diagnosis regarding rare diseases that are clinically unrecognizable,
or baffling, but have a suspected genetic origin.
Neurological diseases are disorders of the brain, spinal cord, and the nerves. There are more
than 600 neurological diseases [1], the major types being genetic (such as Huntington’s disease);
developmental disorders (i.e., cerebral palsy and spina bifida); degenerative diseases (i.e., Alzheimer’s
disease (AD) and Parkinson’s disease (PD)); cerebrovascular diseases (i.e., stroke); physical injuries to
the brain, spinal cord, or nerves; seizure disorders (i.e., epilepsy); brain tumors (i.e., glioma); infection
(i.e., meningitis); mental disorders such as affective and personality disorders (e.g., bipolar disorder
and schizophrenia); sleep disorders (i.e., insomnia); and addictive disorders (i.e., alcoholism) [2].
The neuroinflammatory reaction caused by neurons and non-neuronal cells in neurodegenerative
diseases (NDs) is persistent due to many triggering factors leading to the mutation of genes altering
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proteins implicated in the development of neurodegeneration such as the beta amyloid protein in AD,
the alpha-synuclein protein in PD, and the superoxide dismutase (SOD)-1 mutation in amyotrophic
lateral sclerosis (ALS), as discussed later on [3]. The selective expression in astrocytes and the microglia
per se does not result in motor neurodegeneration [4,5], thereby implying a fundamental role for
surrounding cells during neuron activation. Other studies have focused on the proinflammatory factor
associated with microglial neurotoxicity by deleting factors such as TNF-alpha or interleukin beta as
having a small effect on survival [6,7]. The biological processes promoting these reactions in the glia
are complex and have harmful effects on the motor neurons. Therapeutical interventions directed
against target cells are being explored. A better understanding of the biological and genetic processes
implicated in neuroinflammation will help in defining their importance in ND physiopathology
for identifying potential therapeutic interventions for detaining or differing reactions regarding
neurodegeneration [8].
The field of neurology is not the exception in the explosion of articles/material proclaiming the
usefulness of genetics in identifying genetic risk factors and regarding diagnosis specificity. NDs have
been the target for intensive research in the field of genetics due to their great impact on morbimortality
of adult patients. This article has thus been aimed at reviewing recent advances in the genetic diagnosis
of the following ND: AD, PD, and ALS.
2. Obtaining Genetic Information
2.1. Sanger Sequencing
In 1977, Sanger et al. established the most commonly used method, until recently, for sequencing
a determined fragment of deoxyribonucleic acid (DNA) [9]. It enabled around 500 base pairs to be
sequenced with a 99% specificity; however, the technique is time-consuming for large sequences,
such as in identifying NDs; therefore, new sequencing techniques have emerged. Sanger is the
technique of choice for confirming point mutations found by other methods that could be related to
the onset/appearance of a ND [10]. Figure 1 describes the procedure used for Sanger sequencing [11].
2.2. Next Generation Sequencing (NGS)
NGS incorporates technologies that produce millions of short DNA sequences at low cost and
in a short time, read mostly in the 25 to 700 bp length range for a gene suspected of producing a
disease [12]. It represents an efficient sequencing technique for multiple, short sequences in parallel so
that multiple genes can be sequenced or even the complete human genome. Its main advantages lie in
its rapid sequencing, low cost, and parallel sequencing of multiple genes [13–15]; its disadvantage lies
in the exactitude of the results ranging from 93% to 99%, meaning that it is often thereby necessary to
confirm such results by the Sanger technique. However, it is currently the most used technique due to
its differential advantages. Whole genome sequencing (WGS) has been used for diagnosing NDs or
just the encoding region or exome (i.e., whole exome sequencing (WES)) [16,17]. The large amount of
data obtained by using these techniques has affected the development of informatics departments,
leading to a change in the approach to molecular diagnosis, inverting the pyramid between technology
and interpretation. The techniques most commonly used in diagnosing NDs will be reviewed later on.
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Figure 1. Sanger sequencing [11].
A person’s DNA consists of more than 3000 million nucleotides in the genome, whilst the exome
(the part of the genome which we “understand” is little more than 1% of the genome. Enriching the
exome and sequencing, instead of the whole genome, continues to be the method of choice, essentially
because it is cheaper [18]. However, several companies are rapidly moving toward sequencing
the genome to provide greater coverage; this will facilitate processing more samples and avoiding
expensive PCR artifacts.
The exome is the part of the genome which we think we understand including all the encoding
regions (i.e., about 200,000 exons from 21,000 genes). An exome is little more than 1% of the genome; up
to 85% of all mutations causing disease in Mendelian disorders are found within the encoding exons,
thereby still being the most requested method [19]. WES is indicated when heterogeneous disorders are
suspected (i.e., similar phenotypes in many genes) such as intellectual disability/developmental delay,
epilepsy, muscular dystrophy, ataxia, neuropathy, deafness, or retinitis pigmentosa [20]. Regarding
unclear phenotypes, the technique is also useful when a doctor may not recognize a patient’s possible
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diagnosis (i.e., atypical clinical presentations). It is highly effective in identifying causal variants having
short response times, thereby being economic, is impartial due to being able to evaluate thousands of
genes simultaneously and the fact that dual diagnosis is possible [16,17].
DNA must be isolated and fragmented to enable sequencing the exome; the resulting DNA
fragments are a mixture of introns and exons. The following step consists of separating the exons from
the rest of the genome and sequencing them; the exome must be amplified, and during amplification,
fragmented DNA becomes exposed to the surface containing the whole exome sequence. Then, the
complementary regions (just exons) bind (making hybrids). The remaining DNA (introns) becomes
eliminated in the process. Finally, the exons are sequenced and compared to a reference sequence;
thousands of variants appear (around 60,000 per sample) from such a comparison. All the variants are
filtered until the variants causing a particular disease are detected. Just exon variants can be selected
from the 60,000 variants, thereby reducing the number of variants to be considered to 13,000. This
process is repeated until just a few variants are obtained (about 10). It is then possible to observe which
variants are shared with other members of a (target) family [14,15].
The disadvantages of WES can be divided into two groups: enrichment mechanisms and
coverage difficulties. Regarding enrichment mechanisms, this is the most relevant inconvenience,
especially because when “enriching” the exome by hybridization or amplification, not only are artifacts
introduced into the sequencing and amplify the DNA by PCR, but elements also become introduced as
not all of the regions can be amplified in the same pattern. Regarding coverage, difficulties arise due to
enrichment measures and amplification addressing regions with weak coverage or regions lacking
coverage, and various mutations not being found in the exome (e.g., a regulatory element) and not
being able to be detected [15,17].
WGS will surely replace WES because of its reduced cost; from a methodological point of view, it is
better to have fewer extras, have homogeneous coverage, and a better analysis strategy. Knowledge has
been gained every day when evaluating elements related to parts of the genome which are unrelated to
the exon. Other cases where using WES would be indicated would be an unclear phenotype, atypical
clinical presentations, challenging cases regarding their interpretation, and evaluating results. Other
cases would involve a negative result where the cost can be assumed and when a genetic diagnosis is
required which involves cutting-edge technology [13,14,16,17]. Table 1 summarizes the differences
between WES and WGS.
Table 1. Differences between whole-exome sequencing (WES) and WGS.
WES WGS
Only done in encoding regions (exons) Complete sequence: exons and introns
Cheap and fast Currently expensive
Incomplete analysis of the target region Technology-related challenges: an enormous amountof data is produced
Inclined towards known biology (medically-relevant genes) Increased precision providing information aboutposition and orientation
The Human Phenotype Ontology (HPO) project provides standardized terminology (more
than 10,000 terms) regarding the phenotypical abnormalities found in human genetic syndromes.
Phenotypical characteristics are formally represented as terms on a directed acyclic graph. Multiple
paternity allows the representation of different aspects regarding phenotypical abnormalities [21]. The
HPO’s >10,000 integral, structured, and well-defined terms describe human phenotypical aberrations.
It provides annotations concerning almost 7300 human hereditary syndromes, producing computable
representations of the diseases, genes from associated diseases, signs, symptoms, paraclinical
abnormalities, and other phenotypical anomalous characterizing distinct diseases including ND [22–24].
The authors index different algorithms from the HPO, constructed according to each investigation.
The HPO data provide a powerful tool/resource for translational research, providing the means for
54
Brain Sci. 2018, 8, 222
capturing, storing, and exchanging phenotypical information about pathologies and has been used for
integrating phenotypical information regarding computational analysis [21,22,25–27]. Research results
using NGS (specifically WES and WGS), using clinical analysis for substantially improving candidate
gene ranking, have enabled clinical evaluation based on bioinformatics analysis results to become
integrated into the flow, thereby transforming phenotypical expression in candidate genes [21,28,29].
The strategy of filtering possible variants is designed to highlight rare or de novo mutations as
well as high penetrance mutations modifying proteins. The filtering strategy substantially reduces
the list of candidate variants found in expression concerning the confirmation of their functionality in
an individual.
3. The Genetics of Neurodegenerative Diseases
Studies by Van Deerlin et al. discussed the importance of putting advances in genetic knowledge
regarding NDs into practice, highlighting the correct use of nomenclature, changes in the approach to
identified variants, ethical aspects arising from managing the information, the resources available for
accessing information, and the genetic counselling that patients and their families-care-givers should
receive regarding the diagnosis of a disease having a defined inheritance pattern [30].
Identifying mutations in ND-related genes is important regarding different areas of knowledge
such as basic research, clinical research, clinical characteristics, and identifying biomarkers and images.
The scope of this article focused on identifying the mutations related to each disease.
3.1. Alzheimer’s Disease (AD)
The main cause of dementia affects around 35 million patients around the world [31]; it is produced
by the accumulation of various forms of amyloid proteins and neurofibrillary degeneration [32,33].
Evidence has been presented stating that 58% to 79% of dementias have a genetic component [34].
Inherited family traits have been reported since 1930; they can be explained by an autosomal dominant
model, i.e., 50% risk in the following generation of having a mutation in the amyloid precursor protein
(APP), presenilin 1 (PSEN1), and/or presenilin 2 (PSEN2) genes [33].
The APP gene’s official name is the amyloid beta 4 (A4) precursor protein; APP is mainly found
in the CNS. Kang et al. cloned the gene from chromosome 21 [35,36]. Ryman et al. identified the
factors influencing onset age, onset of symptoms, and the course of autosomal dominant AD including
the Dominantly Inherited Alzheimer Network’s (DIAN) databases, involving two large families from
Colombia (PSEN 1, E280A) and Germany (PSEN 2, Nl41l). A total of 1307 patients were included who
have had a diagnosis of AD; 174 familial mutations were found that correlated with the disease’s onset
age [36,37].
Most variants with an identified risk in more than 20 genes, determined by genome-wide
association studies (GWAS), have not been recognized as affecting protein structure or function,
only conferring 10% to 20% of risk of disease [38]. Other variants in genes have been previously
identified that are not related to AD such as TREM2, UNC 5C, and/or AKAP9; these have a similar
effect on the risk of AD regarding allele APOE E4 [39–42].
APOE, a component of senile plaques [43], has been seen to influence neuritic plaque formation in
models of transgenic mice suffering AD and is also considered to contribute toward AB clearance and its
deposition in the brain [44]. Other in vitro and in vivo studies have suggested that APOE participates
in synaptogenesis, cognition, neurotoxicity, Tau hyperphosphorylation, neuroinflammation, and
cerebral metabolism. APOE e4 is a genetic risk factor that is neither necessary nor sufficient for AD
development [45].
Identifying single-nucleotide polymorphisms (SNP) in the human genome and the development of
SNP genotyping technologies have led to the genetic understanding of commonly occurring complex
diseases [46,47]. More than 600 candidate genes have been studied regarding AD development;
these are regularly updated at the AlzGene website [47,48]. These studies have led to genes such as
the sortilin-related receptor (SORL1) [49] and calcium homeostasis modulator 1 (CALHM1) being
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identified [50], however, the main problems with these genes are the false positives, false negatives,
and heterogeneity in phenotypes, genotypes and potential gene–gene and gene–environment
interaction [48,51,52].
GWAS use large platforms consisting of different SNP markers; it is worth mentioning late onset
AD association studies [53]. GWAS has identified the following candidate genes: the galanin-like
peptide precursor (GALP) [54], phosphoenolpyruvate carboxykinase 1 (PCK1) [55], trafficking
kinesin-binding protein 2 (TRAK2) [54], tyrosine kinase non-receptor 1 (TNK1) [54], the GRB-associated
binding protein 2 (GAB2) [56], Golgi phosphoprotein 2 (GOLPH2) [57], lecithin retinol acyltransferase
(LRAT) [58], and protocadherin 11X (PCDH11X) [59]. Other genes include TRPC4AP, CLU, PICALM,
CR1, LMNA, THEMS, MAPT, and CH25H [54,55,60–62]. Studies have revealed the population
attributable risk (PAR) and association (OR) between the gene presence and AD development via the
relationship with APOE: TOMM40 (OR 2.73, PAR 20.6%) and APOC1 (OR 4.01, PAR 35.1%) [33,54,63].
The clinical implications of genetic discoveries have been mentioned in different studies [52,64,65]
with greater interest being shown in APOE and SORL1, giving a 33% risk for males and 32% for
females aged 75-years old, whilst this rose to 52% for males over 85 and 68% for females over 85-years
old (Table 2). Only 2% of the Caucasian population have the APOE e4/e4 genotype; screening for
APOE has not yet been recommended, but will soon be necessary with the new genetic markers.
Table 2. Dominant autosomal genes regarding AD [33].
Gene Symbol Inheritance Location Risk (%)
Amyloid precursor protein APP Autosomal dominant 21q21.3 38–69
Presenilin 1 PSEN1 Autosomal dominant 14q24.2 25–65
Presenilin 2 PSEN2 Autosomal dominant, reduced penetrance 1q42.13 41–88
3.2. Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic lateral sclerosis (or Lou Gehrig’s disease) is one of the main NDs of the motor
neurons, leading to death within 3 to 5 years following the onset of symptoms. Its prevalence is 1 in 300
people and produces large-scale disability in patients suffering from it. Superoxide dismutase Cu/Zn
or SOD1 was the first ALS-associated gene to be identified in 1993 [66]. Recent advances in genetic
diagnosis have led to discovering other genetic markers using GWAS; familial inheritance occurs in 5%
to 20%. Current knowledge states that more than 20 genes are correlated with the onset of ALS. The
guidelines for the molecular diagnosis of neurogenetic disorders [67] refer to diseases having greater
evidence from genetic exams including familial ALS, bulbar muscular atrophy, Charcot-Marie-Tooth
neuropathy type 1A, myotonic dystrophy, and Duchenne muscular dystrophy.
Even though GWAS has broadened the panorama of genes in different diseases like ALS, other
factors associated with the onset of NDs have been reported in studies on twins and families having
established hereditary components. Further in-depth studies are needed into the genetics as well as
into polygenetics and epigenetics to ensure personalized medicine by finding the factors triggering
diseases [68–70].
Evidence regarding genetic traits in ALS has emerged from studies on twins, demonstrating
the inheritance in the onset of sporadic ALS, ranging from 0.38 to 0.78 (heritability value) [71,72].
However, in addition to the above, two situations hamper the identification of genes in ALS; initially,
the disease is late onset, thereby avoiding the characterization of lineages and prognosis is poor,
thereby hampering follow-up and requiring multicenter studies for sample taking [73–75]. Al-Chalabi
et al. provided a simple explanation for the relationship between genetics and the disease’s pathology,
stressing the presence of protein inclusions in the spinal motor neurons produced by mutated genes
SOD1, TDP43, FUS, and/or OPTN [76].
In 2014, Keller et al. estimated important genetic factors by meta-analysis using GWES databases,
and found a 21% probability of inheritance, identifying 17 regions of the genome having high
significance for the disease [77]. Interestingly, they estimated a 35% inheritance in patients having a
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bulbar presentation, more than 40% inherited cases, and 20% sporadic cases for the hexanucleotide
repeat expansion in C9ORF72 located on the short arm of chromosome 9. Other studies have shown
consistent expansion (hundreds of times) in (GGGGCC), causing neuron loss in the anterior horn of
the spinal cord causing cellular inclusions similar to TDP-43 [78].
The genes related to familial inheritance in ALS (in order of importance) are SOD1, encoding
a copper/zinc superoxide dismutase [66,76] whose alteration produces cytotoxicity, mitochondrial
dysfunction, oxidative stress, axonal aberrations, and is involved in endosome traffic [79–85]. TARDBP
encodes the TDP-43 protein involved in RNA splicing [78]; its alteration produces neuron loss, gliosis,
and Bunin body inclusions in the spinal column’s anterior horn [86,87]. FUS encodes a sarcoma protein
related to RNA processing whose cerebral and spinal mutation causes severe motor neuron loss in the
spinal column [88,89]. UBQLN2 encodes a protein similar to ubiquitin [90], which is responsible for
ubiquitin-mediated protein degradation, whose mutation is X-linked; males suffer from the disease
more frequently than females who have a certain degree of protection [91,92]. TATA-Box Binding
Protein Associated Factor 15 (TAF15) is linked to changes in the TATA-binding protein associated with
factor 15 [93].
The unc-13 homolog A (UNC13A), elongator acetyltransferase complex subunit 3 (ELP3),
homeostatic iron regulator (HFE), angiogenin (ANG), neurofilament heavy (NEFH), and EWS RNA
binding protein 1 (EWSR1) genes have been reported to be associated with sporadic ALS [84,94–101],
as have genes associated with familiar inheritance such as TAF15 [101], C9orf72 [102], C21orf2,
myelin-associated oligodendrocyte basic protein (MOBP), and SCDF1 [103]. Recent WES exome
sequencing has led to finding genes like TANK-binding kinase 1 (TBK1) [104].
Different studies have been carried out on chimeric mice, leading to the inclusion of the SOD1
gene: they have shown cell complex pathways and molecular injury at neuromuscular junctions and
in the cell body of the motor neurons [105–110]. Animal model histology has revealed the destruction
of neuromuscular junctions, whilst numerous inclusions, proximal axon inflammation, mitochondrial
inflammation, vacuoles, and neurofilament accumulations appear in patients [108]. Inadequately
folded proteins including the SOD1 gen protein, and phosphorylate fused neurofilaments in the
sarcoma reflecting physiopathological changes in hereditary and non-hereditary disease [109,110].
The immune and glial cells of transgenic mice with the SOD1 gene affect motor neuron
development, highlighting a multifactorial disease with different mechanisms leading to neuron
injury, involving non-neuron cells such as astrocytes, oligodendrocytes, and microglia for its rapid
progression [110]. Neuroinflammation is the cornerstone in the onset of differing NDs including AD,
PD, multiple sclerosis, and HIV-associated encephalopathy due to intervention in the balance between
neuroprotection and neurotoxicity [111–123].
Nicolas et al. identified a new gene associated with ALS such as the kinesin family member 5A
(KIF5A) using GWAS. In this study, 20,876 cases of ALS were compared with 59,804 controls [124].
Mutations in the KIF5A for the appearance of hereditary spastic paraplegia and Charcot-Marie-Tooth
Type 2 occur in the N-terminal domain, while for ALS they are located in the C-terminal portion
causing defects in the cytoskeleton. This is one of the mechanisms associated with the appearance of
ALS together with alterations in RNA processing and protein homeostasis. The relationship between
the mechanism and the genes associated with ALS are presented in Table 3.
Table 3. Altered pathways in ALS.
Mechanism Mutated Genes
Dynamics of the cytoskeleton PFN1, TUBA4A, DCTN1, and KIF5A
RNA processing C9orf72, TDP-43, FUS, and MATR3
Protein homeostasis UBQLN2, VCP, OPTN, and VAPB
The UNC13A gene in the variant rs12608932 is associated with a lower survival in patients with
ALS, according to the study by Diekstra et al. [125]. A total of 450 sporadic cases of ALS comparing
57
Brain Sci. 2018, 8, 222
survival with 524 controls were analyzed. The UNC13A gene encodes the unc-13 homolog A protein
that is part of a family of presynaptic proteins in the brain. This protein is involved in the regulation of
the release of neurotransmitters in the neuromuscular junction. Another possible gene for intervention
as a possible therapeutic target is the rs2412208 gene of the calmodulin binding transcription activator 1
(CAMTA1) variant whose presence of the GG or GT genotype is associated with a reduction in survival
over four months compared to the TT genotype [126]. The triggering receptor expressed on myeloid
cells 2 (TREM2) variant (p.R47H, rs75932628) increases the risk of AD), but not of frontotemporal lobar
degeneration (FTLD) in ALS and PD [127].
3.3. Parkinson’s Disease (PD)
This is the second most common cause of progressive ND; it affects 30 to 190 patients in 100,000
inhabitants with an average age regarding symptom onset of 60-years old [128]. PD is characterized by
motor symptoms such as bradykinesia, muscular rigidity, resting tremor, and (later on) aberrations
when walking [129]. One of pathological characteristics of PD patients is the progressive loss
pigmented dopaminergic neurons in the black substance (BS) and locus coeruleus, accompanied
by alpha–synuclein-positive Lewy bodies in the remaining neurons [128]. Around 10% are familial
cases, most being sporadic, having mutated genes that have been researched and associated with
an increased risk of the disease’s onset [128]. Animal models have been used for establishing two
possible causes of PD: neurotoxicity and genetic models; the former includes models using pigs,
showing BS neurodegeneration when using neurotoxins such as 6-hydroxydopamine (6-OHDA) or
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [130–132]. Genetically modified pigs have been
unsuccessfully used for identifying the genetic model; however Larsen et al. identified monogenic
PD-associated porcine genes such as LRRK2 (PARK8) sharing a 90% identity with the human genes
responsible for autosomal dominant forms of PD [133]. Other porcine genes are associated with
autosomal recessive forms of PD, but do not fall within the scope of this review (i.e., FBX07, parkin,
DJ-1) [134–136].
NGS technology has been used by several researchers for finding mutations in candidate
genes in familial PD, both autosomal dominant and recessive ones having incomplete penetrance.
Chartier-Harlin et al. [137] studied the exome of PD patients with an autosomal dominant pattern,
finding mutations in EIF4G1. Zamprich et al. also studied the exome of an Austrian family with
16 affected members; they found a mutation in c.1858G>A (p.Asp620Asn) in VPS35 [138]. VPS35 is
an interesting protein, since it is implicated in several Wnt signaling pathways in the biogenesis of
lysosomes [139]. Given the nature of late onset PD, it is difficult to identify mutations that are related
to the disease in different aged family members; however, once identified, they can provide important
information for early diagnosis and treatment of this ND [140].
Genes identified with those to whom the risk of developing PD can be attributed, can be classified
according to the disease’s clinical presentations in cases of autosomal dominant and autosomal
recessive PD [141]. The first autosomal dominant mutation alpha-synuclein (PARK 1 and 4) was
discovered by Nussbaum et al. in 1997 through research on mutations in a large Italian-American
family, finding a genetic lesion on the long arm of chromosome 4 [142]. Research has shown that
this is the major component of Lewy bodies, a pathognomonic marker for all PD; it also produces
severe familial forms and such proteins are present in all forms of PD, in cytoplasmic inclusions in
multiple systemic atrophy, dementia with Lewy bodies, and other ND [141]. The main mutations
found in alpha-synuclein are p.A53T, pA30P, and p.E46K, triplication of the SNCA locus. The most
recent hypothesis deals with alpha-synuclein levels and disease severity and the disease’s late onset
possibly being due to small aberrations in the protein [143]. Another autosomal dominant mutation is
the leucine-rich repeat kinase 2 (LRRK2 or PARK2), located in the pericentromer region of chromosome
12, having reported mutations p.R1441G, p.R1444C, p.Y1699C, p.I1122V, p.I2020T, p.L1114L, and
pG2019S; it is responsible for around 2% of sporadic familial PD cases in different countries [141].
Recent dominant mutations are ATXN2, ATXN3, VPS35 (PARK17), GCH1, MAPT, DCTN1, and EIF4G1.
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The autosomal recessive mutations are parkin (PARK2), DJ1 (PARK7), ATP13A2 (PARK9), FBXO7
(PARK15), and PLA2G6 (PARK14) (see Table 4) [141].
Table 4. Autosomal recessive mutations in PA [141].
Protein Gene Function Location Risk (%)
Parkin [144] PARK2 Ubiquitin proteasomesystem
Cortex, hippocampus, basal
ganglions and cerebellum






Basal nucleus neurons and










the 40s and 50s
On the other hand, it is important to bear in mind that the genome that does not encode a protein
can generate progression to a disease by affecting the normal expression of a gene. The therapeutic
possibility of constructing oligonucleotic antisequencing of the exons is known. However, there are
microRNAs, unions introns/exons, repetitive RNA, and a large number of non-conforming RNA [147].
Matsu et al. presented examples of diseases and the development of drugs or potential therapeutic
targets of the different sequence varieties. In the case of large sequences of non-coding RNA (long
noncoding RNA), they proposed a review of the FANTOMS, ENCODE, and NONCODE database
as well as to determine the subcellular localization of the site of action of the sequence. Specifically,
polycomb repressive complex-2 (PRC2) [148] has been investigated as a regulator of genetic expression
that includes various proteins that modify chromatin and inactivation of the chromosome [149].
Even the non-coding genome is little understood but present in survival associated mitochondrial
melanoma specific oncogenic non-coding RNA [150] (SAMMSON), Angelman’s syndrome [151]
(alteration of the UBE3A gene expression), and metastasis-associated lung adenocarcinoma transcript 1
(MALAT1) [152]. Regarding its presence in neurodegenerative diseases, Wang et al. [153] summarized
the long noncoding RNA associated with AD are BACE1-AS, BC200, 17A, NAT-Rad18, 51A, and
GDNFOS; while those described in PD are NaPINK1, AS Uchl1, HOTAIR, and MALAT1; and in ELA
C9ORF72, FUS/TLS, and TDP43.
4. Conclusions and Perspectives
Genetic tests for diagnosis or detection are necessary for detecting a genetic alteration/aberration
in an affected person or one at risk. Test capacity for/ability to detect a genetic alteration depends on
many factors including gene location, the nature of the mutation, test sensitivity (false negatives), test
specificity (false positives), and reproducibility (including between run, within run, and with different
operators) [154]. There are guidelines for the interpretation of germline multiple variants by means
of criteria to classify the variants as pathogenic, probable pathogenic, uncertain significance, likely
benign, or benign. However, these guidelines have some limitations and there is subjectivity in its
interpretation. Future research should continue to be carried out on bioinformatics and technology
increase. The challenge for clinical laboratories is to ensure that these tests can be integrated into clinical
care [154,155]. There are still many questions concerning the bioinformatic analysis of sequence data
including what should be the threshold for naming variants, what (type of) writing should be used to
register a mutation, and which method should be used for predicting the consequences of a particular
variant. [156]. The European Federation of Neurological Societies (EFNS) guidelines for managing
ALS include DNA analysis for SOD1, SMN, SBMA, TDP43, and FUS amongst the recommended
studies for diagnosing the disease, SOD1 mutation carriers are one of the diagnostic criteria, the use of
riluzole in patients having the SOD1 mutation, the need for genetic exams in cases of a familial history
of ALS, and sporadic cases having the phenotypical characteristics of the D90A recessive mutation.
Genetic diagnosis is not recommended in cases of sporadic ALS with a classical typical phenotype.
SOD1, TARDBP, FUS, or ANG determination is recommendable in familial or sporadic cases having an
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uncertain diagnosis [157]. All patients should receive genetic counselling before any genetic analysis is
made and patients must sign an informed consent form regarding the same.
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Abstract: Metal storage disorders (MSDs) are a set of rare inherited conditions with variable clinical
pictures including neurological dysfunction. The objective of this study was, through a systematic
review, to identify the prevalence of Parkinsonism in patients with MSDs in order to uncover
novel pathways implemented in Parkinson’s disease. Human studies describing patients of any
age with an MSD diagnosis were analysed. Foreign language publications as well as animal
and cellular studies were excluded. Searches were conducted through PubMed and Ovid between
April and September 2018. A total of 53 publications were identified including 43 case reports,
nine cross-sectional studies, and one cohort study. The publication year ranged from 1981 to 2018.
The most frequently identified MSDs were Pantothenate kinase-associated neurodegeneration
(PKAN) with 11 papers describing Parkinsonism, Hereditary hemochromatosis (HH) (7 papers),
and Wilson’s disease (6 papers). The mean ages of onset of Parkinsonism for these MSDs were
33, 53, and 48 years old, respectively. The Parkinsonian features described in the PKAN and HH
patients were invariably atypical while the majority (4/6) of the Wilson’s disease papers had a typical
picture. This paper has highlighted a relationship between MSDs and Parkinsonism. However, due to
the low-level evidence identified, further research is required to better define what the relationship is.
Keywords: Parkinson’s disease; Parkinsonism; metal storage disorders; inborn error of metabolism
1. Introduction
Parkinson’s disease (PD) is a common and debilitating neurodegenerative disorder. First described
in 1817 by James Parkinson, PD is a chronic condition distinguished by bradykinesia, rigidity,
postural instability, and resting tremor often described as “pill-rolling.” The clinical features are
due to the loss of dopaminergic neurones located in the pars compacta of the substantia nigra.
Why these neurons are lost is poorly understood. However, numerous studies from animal models
and familial cases of PD have identified that accumulation of cytoplasmic inclusions of alpha-synuclein
(α-synuclein) called Lewy bodies, oxidative stress, and mitochondrial dysfunction may all play
a pathogenic role in their destruction [1,2].
Despite multiple well-documented risk factors suggesting an environmental association such as
well-water drinking, pesticide exposure, head injury, and rural living [3], only increased age carries
sufficient statistical evidence to be causative [4]. Male gender and Caucasian ethnicity were reported
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to increase the risk of PD in research studies while tobacco smoking has been found to be protective.
Therefore, the existence of other aetiological mechanisms not yet identified must be considered.
Parkinsonism is a clinical picture of a tremor, rigidity, bradykinesia, and postural instability
most frequently caused by sporadic PD. However, it has been described in many other conditions.
Parkinsonism can be associated with additional features such as dystonia, early autonomic dysfunction,
a rapidly progressive disease course, or levodopa unresponsiveness [5]. In this instance, it is described
as atypical Parkinsonism since it differs from the typical clinical picture seen in Parkinson’s disease.
Inborn errors of metabolism (IEMs) are a large collection of individually rare but collectively
common inherited conditions [6]. They are a diverse set of conditions that occur as a result of
a monogenic mutation resulting in a deficiency of an enzyme or cofactor [7]. Metal storage disorders
are a large subset of these.
Studies have found that patients with PD have increased levels of iron accumulation in the basal
ganglia compared with healthy controls [8]. Research has also been conducted into the potential
toxic mechanisms of iron causing nigral cell death and leading to PD features in sporadic PD patients
even though it remains unclear whether neuronal death is a direct result of iron accumulation or if
the accumulation is a by-product of dopaminergic cell death [9].
This systematic review aims to identify whether there is a wider pathological link between
PD and metal storage disorders by exploring published accounts of Parkinsonism in patients
with a previously diagnosed metal storage disorder. Identifying other conditions that produce
Parkinsonian-like clinical features may uncover novel pathological mechanisms that contribute to
the development of PD. In addition, this paper will discuss whether the clinical features seen in
the patients with metal storage disorders displaying Parkinsonism are of a typical picture seen in PD
or if they are more similar to atypical Parkinsonism.
2. Materials and Methods
This systematic review was conducted by following the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) 2009 guidance [10].
2.1. Search Terms
Systematic literature searches were conducted in the PubMed and Ovid SP databases including
all published articles prior to the search date. The last search was completed on 6 September, 2018.
The titles and abstracts were searched by combining two search terms (Term A and Term B). Term A
was ‘Parkinson,’ ‘Parkinson’s,’ ‘Parkinsonism,’ or ‘Parkinsonian’ while Term B included each of
the individual metal storage disorders. A list of metal storage disorders was collated from a relevant
review article [11]. A full list of the search terms can be found in Appendix A.
2.2. Inclusion Criteria
Human studies of all designs were considered except review articles. Only publications describing
patients with a definite genomic or biochemical diagnosis of a metal storage disorder were analysed.
Publications reporting adults, children, and infants were all included since metal storage disorders
and Parkinsonian features can present at any age. Cohorts from all nationalities and ethnic backgrounds
were also included.
2.3. Exclusion Criteria
Animal and cellular model studies were excluded as well as autopsy reports. Papers describing
PD patients with MSD associated gene mutations were also excluded unless they had a confirmed
diagnosis of that disorder. Publications written in languages other than English, without whole
text translations available, were excluded. Reviews and letters to editors were also excluded
but the references examined to identify any potentially relevant references that the searches had
omitted were accepted.
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2.4. Selection Process
The publications acquired from the searches were screened in line with the selection criteria by
reading the titles and abstracts to assess relevance. Afterward, full texts were sought for all papers
eligible for inclusion. Two reviewers conducted this screening process to ensure adherence to selection
criteria. Conflicts were resolved through discussion between the reviewers.
2.5. Data Extraction
The primary outcomes extracted from the publications were the type of study, the IEM affecting
the patients reported in the study, and whether the patient had features of typical or atypical
Parkinsonism. Patients were identified as possessing atypical Parkinsonism if there was evidence
of early autonomic dysfunction, a rapidly progressive course, lack of asymmetrical features at
onset, and a poor response to conventional levodopa therapy or a Parkinson-Plus syndrome, as per
the definition in the introduction. Where available, the gender, age of onset of Parkinsonian features,
smoking status, and ethnicity were recorded as secondary outcomes. A breakdown of the data collected
from each individual paper including the clinical picture of the patients can be found in Table A1.
3. Results
In total, 967 publications were identified corresponding to 827 unique articles which underwent
the screening process. Following the title and abstract review, 730 were excluded since they did
not satisfy the inclusion criteria. Following full text screening, a further 53 records were excluded.
Six additional relevant publications were identified from hand searching the reference lists of
the reviews and letters identified in the searches. A total of 50 papers were included in this review.
Figure 1 shows a PRISMA flowchart of the selection process. The final group of articles consisted
of 40 (80.0%) case reports and series, nine (18.0%) cross-sectional studies, and one (2.0%) cohort study
(Table 1). The year of publications ranged from 1981 to 2018 with three (6.0%) papers published before
1990, three (6.0%) papers published in the decade between 1991 to 2000, 12 (24.0%) papers published
from 2001 to 2010, and 32 (64.0%) papers published in the current decade from 2011 to 2018 (Table 1).
Table 1. Characteristics of included publications.
Year of Publication Range 1981–2018









Typical Parkinsonism was reported in 16 (32.0%) publications and atypical in 38 (76.0%)
publications, which is shown in Table 2. Of these papers, four described subjects with both typical
and atypical features. Additionally, 173 patients were reported to have Parkinsonism, 86 (49.7%)
were male, and the average age of onset was 35 years old. The ratio of males to females observed
was 0.99:1 (86 males to 87 females). The smoking status was not reported in any of the publications
(Appendix B).
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Figure 1. Prisma flow chart illustrating the search strategy and the selection process.
Pantothenate kinase-associated neurodegeneration (PKAN), which is the most prevalent
neurodegenerative brain iron accumulation (NBIA) disorder, was the most documented metal
storage disorder and was reported in 11 papers. All of these publications described patients
displaying features of atypical Parkinsonism. Three papers also described subjects with typical
Parkinsonian features. Within the 85 PKAN patients reflected by these articles, the mean age of
onset of Parkinsonism was 33 years old. The gender ratio was 1.36:1 with 49 males and 36 females
described. PLA2G6-associated neurodegeneration (PLAN) was another frequently identified
NBIA with three publications identified. Typical parkinsonism features were described by two of these
papers while the remaining publications reported atypical Parkinsonism. Other NBIAs identified
beta-propeller protein-associated neurodegeneration (BPAN) with five publications (four with
atypical Parkinsonism and one with typical features), Kufor-Rakeb Syndrome with five articles
(all atypical, although one described patients with typical features), and mitochondrial-membrane
protein-associated neurodegeneration (MPAN) (three papers describing atypical parkinsonism).
In addition, three publications described atypical features in subjects with neuroferritinopathy and one
paper described a patient with Aceruloplasminemia presenting with features of atypical Parkinsonism.
An additional paper described a subject with atypical features who suffered from an unknown type
of NBIA.
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After PKAN and NBIAs, the next most reported metal storage disorders were Hereditary
Haemochromatosis (HH) and Wilson’s disease. Seven articles were identified that reported patients
with HH and four papers (57.1%) described typical Parkinsonism. In these publications, 14 subjects
were described including 10 males and 4 females (a ratio of 2.5:1). The mean age of onset of
Parkinsonism in these patients was calculated at 53 years of age. Parkinsonism in Wilson’s disease
patients was reported in six papers in which four (66.6%) described typical features while the remaining
two papers (33.3%) displayed atypical pictures. The mean age of onset in the patients described
was 46 years of age and a gender ratio 0.75:1 (three males and six females).
4. Discussion
Parkinsonian presentation in patients with metal storage disorders is an area of growing
interest. The number of publications identified in this study increases each decade. While only three
articles were published earlier than 1990, between the years 2010 to 2018, 29 papers were identified.
This demonstrates an increasing amount of research being conducted in this field and a growing
appreciation for a possible correlation between Parkinsonism and metal storage disorders.
The family of neurodegenerative brain iron accumulation (NBIA) disorders includes Pantothenate
kinase-associated neurodegeneration (PKAN), Aceruloplasminemia, beta-propeller protein-associated
neurodegeneration (BPAN), Kufor-Rakeb Syndrome, mitochondrial-membrane protein-associated
neurodegeneration (MPAN), neuroferritinopathy, and PLA2G6-associated neurodegeneration (PLAN).
Articles discussing all of these disorders were identified by our searches and described patients
displaying Parkinsonism. These all showed a similar phenotype with young average ages
of onset of Parkinsonism ranging from 13 years old (Kufor-Rakeb syndrome) to 61 years old
(neuroferritinopathy) and predominantly atypical Parkinsonian features. This reflects the similar
pathologies across the NBIA family of disorders. In all NBIAs, increased deposition of iron in brain
tissue is observed. It is unclear whether this deposition is the direct cause of neurodegeneration or if
it is simply a marker of the degeneration occurring as a result of some other pathological mechanism.
However, Parkinsonism as well as dystonia appears well documented across all NBIAs.
In line with our findings, PKAN is the most common NBIA accounting for roughly half of all
cases [12]. In the 11 publications describing PKAN, all papers described patients with atypical features
while three also described patients with typical Parkinsonism. The atypical features displayed in
these patients were a poor levodopa response [13–16], a lack of asymmetrical features [15,17–19],
or the presence of dystonia in addition to Parkinsonism [14,20–22] (Appendix B). In two publications,
pyramidal signs were also observed [19,23]. Recent research has established that Lewy body pathology
is not observed in PKAN, which may explain why atypical features of Parkinsonism are more
commonly seen [24]. Historical reports of patients with PKAN have found α-synuclein inclusions
in neurons [7,25]. However, Schneider et al. believe these patients may have been misdiagnosed
since these reports were published before gene identification was available for diagnosing PKAN [24].
They describe a recent series of genetically confirmed PKAN patients in which all lacked any evidence
of Lewy body pathology. This suggests a differing pathology is occurring in these patients. Our results
showing a high prevalence of atypical Parkinsonism in PKAN sufferers supports this hypothesis.
At the same time, the widespread presence of α-synuclein inclusions in the central nervous system
(CNS) tissue of PLAN patients is well documented [26,27], which indicates a potential pathological link
between PLAN and sporadic PD. The results from this review support this link with two of the three
publications describing patients with PLAN due to features of typical Parkinsonism [28,29]. In the one
paper describing atypical parkinsonism features in patients with PLAN, dystonia was present [30].
Hereditary haemochromatosis (HH) was also frequently identified in this systematic review.
Four papers reported typical Parkinsonism [31–34] while atypical features were described in
the remaining three papers. All papers were related to unresponsiveness to levodopa [35–37].
These reports of Parkinsonism and HH presenting concurrently indicate that research into iron
accumulation in the CNS tissue of HH patients may clarify the pathological link between HH and PD.
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The pathological processes and brain regions involved in HH are not well understood. In particular,
the location of iron accumulation in CNS tissue is poorly documented. Since Parkinson’s disease
treatments were reported to be ineffective in these patients and an atypical picture was observed,
it may be that a different area of the brain is affected. Further research is required in order to identify
how and where the iron accumulation occurs in order to draw further conclusions from this result.
Six publications described Parkinsonism in Wilson’s disease. It is well established that copper
deposition, as seen in Wilson’s disease patients, commonly has toxic effects in the brain, which leads
to severe neurological features [38,39]. How copper causes neuronal death is not well understood
even though it is generally accepted that the copper accumulates extracellularly and does not enter
neurons [38]. Within this group, four publications described typical Parkinsonism in Wilson’s
disease [40–43] and two described atypical parkinsonism [44,45]. Although Parkinsonism is a common
feature of neurologic Wilson’s disease [38,39], there is no evidence to suggest that Wilson’s disease
causes Lewy body pathology. Despite this, all of the Wilson’s Disease patients from this study
displayed levodopa responsiveness. This included two patients with atypical parkinsonism where
one had dystonia [44] and one had epilepsy [45]. As mitochondrial dysfunction plays a large
role in the pathophysiology of PD [1,2], the extracellular accumulation of copper in the CNS
may have the same effect on mitochondria within the neuron that it does within the hepatocytes.
Despite the similarities in clinical features and the response to levodopa, these patients’ demographics
differ significantly to those seen in the sporadic PD population, which is outlined by Rizek et al. [46].
The average age of onset of Parkinsonism in these Wilson’s disease patients was reported as 46 years
old, which is considerably younger than in the sporadic PD population (mean age 65 years
old). Furthermore, twice as many females as males were described as having Parkinsonism,
which differs greatly to the ratio of 1.5 males per females seen in the sporadic PD population.
However, since only nine patients were described, this is not a large enough population to draw
generalizable conclusions especially since the lack of α-synuclein pathology indicates the presence of
a different pathological process.
Despite previous research establishing that cigarette smoking is protective for PD [4], the smoking
status was not reported in any of the publications (Appendix B). Therefore, it was not possible to
investigate this in the current study. It would be pertinent to include the smoking status in the patient
demographics of all future publications describing PD or features of Parkinsonism.
The precise nature of the relationship between iron accumulation in patients with Parkinsonism
is not clear. Autopsy studies were excluded from this review since they offered retrospective details of
the clinical picture and the timelines were poorly outlined. However, they could yield some useful
findings in patients with metal storage disorders. Post mortem brain studies on patients with NBIAs
allows us to investigate the correlation between the quantity of iron and the severity of PD features.
Should this confirm that iron accumulation in the brain leads to the development of Parkinsonism,
it follows that treatments to reduce the CNS iron levels, or act as an iron chelator, could be developed
as an early treatment for patients with sporadic PD in order to delay the Parkinsonian features.
An important factor to consider when interpreting these results is the level and quality of evidence
available in the literature. The majority of the publications included were case reports and case series
that the Oxford Centre of Evidence-Based Medicine considers level 4 evidence [47]. However, due to
the rarity of these individual IEMs, this was the highest level of evidence available. Case reports can be
subject to bias and, although no formal bias assessment was conducted, a more favourable response
to levodopa or exaggeration of the severity of the features may have been reported. This was taken
into consideration when evaluating articles for inclusion and any paper describing a response less
than moderate to levodopa was classed as atypical.
5. Conclusions
In conclusion, the presence of Parkinsonism in metal storage disorders is an under reported topic.
Establishing the relationships between these conditions may clarify the pathological mechanisms of
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Parkinsonism. Therefore, it is a field of growing interest with the number of publications describing
patients with metal storage disorders displaying Parkinsonism growing substantially each decade.
This review has demonstrated the following:
1. There is evidence of Parkinsonism coexisting with metal storage disorders in particular
neurodegenerative brain iron accumulation disorders.
2. Patients with these metal storage disorders have an earlier age of onset of Parkinsonism
than sporadic PD patients, which suggests additional underlying pathological processes are
taking place. The ratio of males to females seen in many of these also differs significantly to
the sporadic PD population, which further indicates a differing pathogenesis.
3. Future research must be conducted at a higher level than individual case reports to better assess
the relationship between metal storage disorders and Parkinsonism. Cohort studies or case
control studies using large cohorts will lead to a reliable dataset. At the same time, research in
sporadic PD patients will identify whether any of the pathological mutations or processes are
involved in the disorders discussed in relation to the development of Parkinsonism.
4. Smoking status and ethnicity should be documented in all future studies of Parkinsonism since
Caucasian ethnicity is a large risk factor in sporadic PD while cigarette smoking appears to be
protective. Recording these demographics will allow for the investigation of their presence in
patients with metal storage disorders.
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Appendix A.
Search terms. Term A: Parkinson, Parkinson’s, Parkinsonism, Parkinsonism. Term B:
Aceruloplasminemia, Acrodermatitis, Bartter disease, BPAN, Calcium metabolism, CoPAN,
Copper metabolism, DiGeorge, Fahr, Hemochromatosis, Hereditary rickets, Iron metabolism,
Kufor-Rakeb syndrome, Magnesium metabolism, Menkes, Mitochondrial membrane protein-associated
neurodegeneration, Neurodegenerative brain iron accumulation, Neuroferritinopathy, PLAN,
PLA2G6-associated neurodegeneration, Phosphate metabolism, Pseudohypoparathyroidism,
Tumoral calcinosis, Vitamin D metabolism, Wilson, Woodhouse-Sakati syndrome, Zinc metabolism.
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